U.S. patent application number 10/825026 was filed with the patent office on 2005-05-26 for tumor antigen bfa5 for prevention and / or treatment of cancer.
This patent application is currently assigned to Aventis Pasteur, Ltd.. Invention is credited to Berinstein, Neil, Gallichan, Scott, Lovitt, Corey, Parrington, Mark, Pedyczak, Artur, Radvanyi, Laszlo, Singh-Sandhu, Devender.
Application Number | 20050112099 10/825026 |
Document ID | / |
Family ID | 33300017 |
Filed Date | 2005-05-26 |
United States Patent
Application |
20050112099 |
Kind Code |
A1 |
Berinstein, Neil ; et
al. |
May 26, 2005 |
Tumor antigen BFA5 for prevention and / or treatment of cancer
Abstract
The present invention relates to a nucleic acid encoding a
polypeptide and the use of the nucleic acid or polypeptide in
preventing and/or treating cancer. In particular, the invention
relates to improved vectors for the insertion and expression of
foreign genes encoding tumor antigens for use in immunotherapeutic
treatment of cancer.
Inventors: |
Berinstein, Neil; (Toronto,
CA) ; Gallichan, Scott; (Campbellville, CA) ;
Lovitt, Corey; (Bolton, CA) ; Parrington, Mark;
(Bradford, CA) ; Pedyczak, Artur; (Pickering,
CA) ; Radvanyi, Laszlo; (Richmond Hill, CA) ;
Singh-Sandhu, Devender; (Thornhill, CA) |
Correspondence
Address: |
Patrick J. Halloran, Aventis Pasteur, Inc.
Intellectual Property, Knerr Bldg.
One Discovery Drive
Swiftwater
PA
18370
US
|
Assignee: |
Aventis Pasteur, Ltd.
1755 W. Steeles Ave.
Toronto
CA
|
Family ID: |
33300017 |
Appl. No.: |
10/825026 |
Filed: |
April 15, 2004 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
60462945 |
Apr 15, 2003 |
|
|
|
Current U.S.
Class: |
424/93.2 ;
435/320.1; 435/325; 435/456; 435/69.1; 530/350; 536/23.5 |
Current CPC
Class: |
A61P 35/00 20180101;
A61P 37/04 20180101; C07K 14/47 20130101 |
Class at
Publication: |
424/093.2 ;
435/456; 435/069.1; 435/320.1; 435/325; 530/350; 536/023.5 |
International
Class: |
C07H 021/04; A61K
048/00; C07K 014/47; C12N 015/86 |
Claims
What is claimed is:
1. An expression vector comprising the nucleic acid sequence as
illustrated in SEQ ID NO.: 5 or FIG. 4; a nucleic acid sequence
encoding the amino acid sequence illustrated in SEQ ID NO.: 6 or
FIG. 5; or a fragment thereof.
2. The expression vector of claim 1 wherein the vector is a plasmid
or a viral vector.
3. The expression vector of claim 2 wherein the viral vector is
selected from the group consisting of poxvirus, adenovirus,
retrovirus, herpesvirus, and adeno-associated virus.
4. The expression vector of claim 3 wherein the viral vector is a
poxvirus selected from the group consisting of vaccinia, NYVAC,
avipox, canarypox, ALVAC, ALVAC(2), fowlpox, and TROVAC.
5. The expression vector of claim 4 wherein the viral vector is a
poxvirus selected from the group consisting of NYVAC, ALVAC, and
ALVAC(2).
6. The expression vector of claim 1 further comprising at least one
additional tumor-associated antigen.
7. The expression vector of claim 6 wherein the vector is a plasmid
or a viral vector.
8. The expression vector of claim 7 wherein the viral vector is
selected from the group consisting of poxvirus, adenovirus,
retrovirus, herpesvirus, and adeno-associated virus.
9. The expression vector of claim 8 wherein the viral vector is a
poxvirus selected from the group consisting of vaccinia, NYVAC,
avipox, canarypox, ALVAC, ALVAC(2), fowlpox, and TROVAC.
10. The expression vector of claim 9 wherein the viral vector is a
poxvirus selected from the group consisting of NYVAC, ALVAC, and
ALVAC(2).
11. The expression vector of claim 1 further comprising at least
one nucleic sequence encoding an angiogenesis-associated
antigen.
12. The expression vector of claim 1 wherein the vector is a
plasmid or a viral vector.
13. The expression vector of claim 12 wherein the viral vector is
selected from the group consisting of poxvirus, adenovirus,
retrovirus, herpesvirus, and adeno-associated virus.
14. The expression vector of claim 13 wherein the viral vector is a
poxvirus selected from the group consisting of vaccinia, NYVAC,
avipox, canarypox, ALVAC, ALVAC(2), fowlpox, and TROVAC.
15. The expression vector of claim 14 wherein the viral vector is a
poxvirus selected from the group consisting of NYVAC, ALVAC, and
ALVAC(2).
16. The expression vector of claim 6 further comprising at least
one nucleic sequence encoding an angiogenesis-associated
antigen.
17. The expression vector of claim 16 wherein the vector is a
plasmid or a viral vector.
18. The expression vector of claim 17 wherein the viral vector is
selected from the group consisting of poxvirus, adenovirus,
retrovirus, herpesvirus, and adeno-associated virus.
19. The expression vector of claim 17 wherein the viral vector is a
poxvirus selected from the group consisting of vaccinia, NYVAC,
avipox, canarypox, ALVAC, ALVAC(2), fowlpox, and TROVAC.
20. The expression vector of claim 18 wherein the viral vector is a
poxvirus selected from the group consisting of NYVAC, ALVAC, and
ALVAC(2).
21. An expression vector selected from the group consisting of an
expression vector of claim 1, an expression vector of claim 6, an
expression vector of claim 11, and an expression vector of claim
16; further comprising a nucleic acid sequence encoding a
co-stimulatory molecule.
22. The expression vector of claim 22 wherein the vector is a
plasmid or a viral vector.
23. The expression vector of claim 23 wherein the viral vector is
selected from the group consisting of poxvirus, adenovirus,
retrovirus, herpesvirus, and adeno-associated virus.
24. The expression vector of claim 24 wherein the viral vector is a
poxvirus selected from the group consisting of vaccinia, NYVAC,
avipox, canarypox, ALVAC, ALVAC(2), fowlpox, and TROVAC.
25. The expression vector of claim 18 wherein the viral vector is a
poxvirus selected from the group consisting of NYVAC, ALVAC, and
ALVAC(2).
26. A composition comprising an expression vector in a
pharmaceutically acceptable carrier, said vector comprising the
nucleic acid sequence shown in SEQ ID NO.:5 or FIG. 4; a nucleic
acid sequence encoding the amino acid sequence illustrated in SEQ
ID NO.: 6 or FIG. 5; or a fragment thereof.
27. The composition of claim 26 wherein the vector is a plasmid or
a viral vector.
28. The composition of claim 27 wherein the viral vector is
selected from the group consisting of poxvirus, adenovirus,
retrovirus, herpesvirus, and adeno-associated virus.
29. The composition of claim 28 wherein the viral vector is a
poxvirus selected from the group consisting of vaccinia, NYVAC,
avipox, canarypox, ALVAC, ALVAC(2), fowlpox, and TROVAC.
30. The composition of claim 29 wherein the viral vector is a
poxvirus selected from the group consisting of NYVAC, ALVAC, and
ALVAC(2).
31. A method for preventing or treating cancer comprising
administering to a host an expression vector comprising the nucleic
acid sequence illustrated in SEQ ID NO.: 5 or FIG. 4; a nucleic
acid encoding the amino acid sequence illustrated in SEQ ID NO.: 6
or FIG. 5; or a fragment thereof.
32. The method of claim 31 wherein the vector is a plasmid or a
viral vector.
33. The method of claim 32 wherein the viral vector is selected
from the group consisting of poxvirus, adenovirus, retrovirus,
herpesvirus, and adeno-associated virus.
34. The method of claim 33 wherein the viral vector is a poxvirus
selected from the group consisting of vaccinia, NYVAC, avipox,
canarypox, ALVAC, ALVAC(2), fowlpox, and TROVAC.
35. The method of claim 34 wherein the viral vector is a poxvirus
selected from the group consisting of NYVAC, ALVAC, and
ALVAC(2).
36. An isolated peptide derived from BFA5 as shown in Table X or
XI.
37. A method for immunizing a host against the tumor antigen BFA5
comprising administering to the patient a peptide shown in Table X
or XI, either alone or in combination with another agent, where the
individual components of the combination are administered
simultaneously or separately from one another.
38. An isolated peptide derived from BFA5 as shown in Table X or
XI.
39. A method for immunizing a host against the tumor antigen BFA5
comprising administering to the patient a peptide shown in Table X
or XI, either alone or in combination with another agent, where the
individual components of the combination are administered
simultaneously or separately from one another.
40. The expression vector of claim 6 wherein the additional
tumor-associated antigen is encoded by a nucleic acid sequence
selected from the group consisting of SEQ ID NO.: 1; SEQ ID NO.: 3;
the nucleic acid sequence shown in FIG. 1; the nucleic sequence
illustrated in FIG. 3A; a nucleic acid sequence encoding the amino
acid sequence of SEQ ID NO.: 2; a nucleic acid sequence encoding
the amino acid sequence of SEQ ID NO.: 4; the nucleic acid sequence
encoding the amino acid sequence illustrated in FIG. 2; a nucleic
acid sequence encoding the amino acid sequence illustrated in FIG.
3B; a nucleic acid hybridizable under stringent conditions to any
of the foregoing sequences; a fragment of any of the foregoing
nucleic acid sequences; and, a derivative of any of the foregoing
nucleic acid sequences.
41. The expression vector of claim 40 wherein the viral vector is
selected from the group consisting of poxvirus, adenovirus,
retrovirus, herpesvirus, and adeno-associated virus.
42. The expression vector of claim 41 wherein the viral vector is a
poxvirus selected from the group consisting of vaccinia, NYVAC,
avipox, canarypox, ALVAC, ALVAC(2), fowlpox, and TROVAC.
43. The expression vector of claim 42 wherein the viral vector is a
poxvirus selected from the group consisting of NYVAC, ALVAC, and
ALVAC(2).
44. An expression vector selected from the group consisting of an
expression vector of claim 40, an expression vector of claim 41, an
expression vector of claim 42, and an expression vector of claim
42; further comprising a nucleic acid sequence encoding a
co-stimulatory molecule.
45. An expression vector of claim 44 or claim 21 wherein the
co-stimulatory molecule is human B7.1 or a derivative thereof.
46. A composition comprising an expression vector of claim 40 in a
pharmaceutically acceptable carrier.
47. A composition comprising an expression vector of claim 41 in a
pharmaceutically acceptable carrier.
48. A composition comprising an expression vector of claim 42 in a
pharmaceutically acceptable carrier.
49. A composition comprising an expression vector of claim 43 in a
pharmaceutically acceptable carrier.
50. A composition comprising an expression vector of claim 44 in a
pharmaceutically acceptable carrier.
51. A composition comprising an expression vector of claim 45 in a
pharmaceutically acceptable carrier.
52. A method for preventing or treating cancer comprising
administering to a host a composition of claim 46.
53. A method for preventing or treating cancer comprising
administering to a host a composition of claim 47.
54. A method for preventing or treating cancer comprising
administering to a host a composition of claim 48.
55. A method for preventing or treating cancer comprising
administering to a host a composition of claim 49.
56. A method for preventing or treating cancer comprising
administering to a host a composition of claim 50.
57. A method for preventing or treating cancer comprising
administering to a host a composition of claim 51.
58. An isolated DNA molecule comprising the nucleic acid of SEQ ID
NO.:5 and at least one of the nucleic acid sequences of SEQ ID NO.:
3 or SEQ ID NO.: 5.
59. An expression vector comprising the isolated DNA molecule of
claim 58.
60. An isolated DNA molecule comprising a nucleic acid encoding the
amino acid sequence of SEQ ID NO. 6 and at least one of the amino
acid sequences of SEQ ID NO.: 2 or SEQ ID NO.: 4.
61. An expression vector comprising the isolated DNA molecule of
claim 60.
62. An isolated DNA molecule comprising the nucleic acid of SEQ ID
NO.:5 and at least one of the nucleic acid sequences of SEQ ID NO.:
3 or SEQ ID NO.: 5; a nucleic acid hybridizable under stringent
conditions to the nucleic acid sequences of SEQ ID NO.: 3 or SEQ ID
NO.: 5; a fragment of the nucleic acid sequences of SEQ ID NO.: 3
or SEQ ID NO.: 5; and, a derivative of any of the nucleic acid
sequences of SEQ ID NO.: 3 or SEQ ID NO.: 5.
63. An antibody having the ability to bind the amino acid sequence
of SEQ ID NO.: 6 or a fragment the amino acid sequence of SEQ ID
NO.: 6.
Description
RELATED APPLICATIONS
[0001] This application claims priority to U.S. Provisional
Application No. 60/462,945 filed Apr. 15, 2003.
FIELD OF THE INVENTION
[0002] The present invention relates to a nucleic acid encoding a
polypeptide and the use of the nucleic acid or polypeptide in
preventing and/or treating cancer. In particular, the invention
relates to improved vectors for the insertion and expression of
foreign genes encoding tumor antigens for use in immunotherapeutic
treatment of cancer.
BACKGROUND OF THE INVENTION
[0003] There has been tremendous increase in last few years in the
development of cancer vaccines with Tumour-associated antigens
(TAAs) due to the great advances in identification of molecules
based on the expression profiling on primary tumours and normal
cells with the help of several techniques such as high density
microarray, SEREX, immunohistochemistry (IHC), RT-PCR, in-situ
hybridization (ISH) and laser capture microscopy (Rosenberg,
Immunity, 1999; Sgroi et al, 1999, Schena et al, 1995, Offringa et
al, 2000). The TAAs are antigens expressed or over-expressed by
tumour cells and could be specific to one or several tumours for
example CEA antigen is expressed in colorectal, breast and lung
cancers. Sgroi et al (1999) identified several genes differentially
expressed in invasive and metastatic carcinoma cells with combined
use of laser capture microdissection and cDNA microarrays. Several
delivery systems like DNA or viruses could be used for therapeutic
vaccination against human cancers (Bonnet et al, 2000) and can
elicit immune responses and also break immune tolerance against
TAAs. Tumour cells can be rendered more immunogenic by inserting
transgenes encoding T cell co-stimulatory molecules such as B7.1 or
cytokines such as IFN-.gamma., IL2, or GM-CSF, among others.
Co-expression of a TAA and a cytokine or a co-stimulatory molecule
has also been shown to be useful in developing effective
therapeutic vaccines (Hodge et al, 95, Bronte et al, 1995,
Chamberlain et al, 1996).
[0004] There is a need in the art for reagents and methodologies
useful in stimulating an immune response to prevent or treat
cancers. The present invention provides such reagents and
methodologies which overcome many of the difficulties encountered
by others in attempting to treat cancer.
SUMMARY OF THE INVENTION
[0005] The present invention provides an immunogenic target for
administration to a patient to prevent and/or treat cancer. In
particular, the immunogenic target is a tumor antigen ("TA") and/or
an angiogenesis-associated antigen ("AA"). In one embodiment, the
immunogenic target is encoded by SEQ ID NO.: 5 or has the amino
acid sequence of SEQ ID NO.: 6. In certain embodiments, the TA
and/or AA are administered to a patient as a nucleic acid contained
within a plasmid or other delivery vector, such as a recombinant
virus. The TA and/or AA may also be administered in combination
with additional tumor antigens (i.e., SEQ ID NOS.: 1-4) and/or an
immune stimulator, such as a co-stimulatory molecule or
adjuvant.
BRIEF DESCRIPTION OF THE DRAWINGS
[0006] FIG. 1. BFA4 cDNA sequence.
[0007] FIG. 2. BFA4 amino acid sequence.
[0008] FIG. 3. BCY1 nucleotide (A) and amino acid (B)
sequences.
[0009] FIG. 4. BFA5 cDNA sequence.
[0010] FIG. 5. BFA5 amino acid sequence.
DETAILED DESCRIPTION
[0011] The present invention provides reagents and methodologies
useful for treating and/or preventing cancer. All references cited
within this application are incorporated by reference.
[0012] In one embodiment, the present invention relates to the
induction or enhancement of an immune response against one or more
tumor antigens ("TA") to prevent and/or treat cancer. In certain
embodiments, one or more TAs may be combined. In preferred
embodiments, the immune response results from expression of a TA in
a host cell following administration of a nucleic acid vector
encoding the tumor antigen or the tumor antigen itself in the form
of a peptide or polypeptide, for example.
[0013] As used herein, an "antigen" is a molecule such as a
polypeptide or a portion thereof that produces an immune response
in a host to whom the antigen has been administered. The immune
response may include the production of antibodies that bind to at
least one epitope of the antigen and/or the generation of a
cellular immune response against cells expressing an epitope of the
antigen. The response may be an enhancement of a current immune
response by, for example, causing increased antibody production,
production of antibodies with increased affinity for the antigen,
or an increased or more effective cellular response (i.e.,
increased T cells or T cells with higher anti-tumor activity). An
antigen that produces an immune response may alternatively be
referred to as being immunogenic or as an immunogen. In describing
the present invention, a TA may be referred to as an "immunogenic
target".
[0014] TA includes both tumor-associated antigens (TAAs) and
tumor-specific antigens (TSAs), where a cancerous cell is the
source of the antigen. A TAA is an antigen that is expressed on the
surface of a tumor cell in higher amounts than is observed on
normal cells or an antigen that is expressed on normal cells during
fetal development. A TSA is an antigen that is unique to tumor
cells and is not expressed on normal cells. TA further includes
TAAs or TSAs, antigenic fragments thereof, and modified versions
that retain their antigenicity.
[0015] TAs are typically classified into five categories according
to their expression pattern, function, or genetic origin:
cancer-testis (CT) antigens (i.e., MAGE, NY-ESO-1); melanocyte
differentiation antigens (i.e., Melan A/MART-1, tyrosinase, gp100);
mutational antigens (i.e., MUM-1, p53, CDK-4); overexpressed `self`
antigens (i.e., HER-2/neu, p53); and, viral antigens (i.e., HPV,
EBV). For the purposes of practicing the present invention, a
suitable TA is any TA that induces or enhances an anti-tumor immune
response in a host in whom the TA is expressed. Suitable TAs
include, for example, gp100 (Cox et al., Science, 264:716-719
(1994)), MART-1/Melan A (Kawakami et al., J. Exp. Med., 180:347-352
(1994)), gp75 (TRP-1) (Wang et al., J. Exp. Med., 186:1131-1140
(1996)), tyrosinase (Wolfel et al., Eur. J. Immunol., 24:759-764
(1994); WO 200175117; WO 200175016; WO 200175007), NY-ESO-1 (WO
98/14464; WO 99/18206), melanoma proteoglycan (Hellstrom et al., J.
Immunol., 130:1467-1472 (1983)), MAGE family antigens (i.e.,
MAGE-1,2,3,4,6,12, 51; Van der Bruggen et al., Science,
254:1643-1647 (1991); U.S. Pat. Nos. 6,235,525; CN 1319611), BAGE
family antigens (Boel et al., Immunity, 2:167-175 (1995)), GAGE
family antigens (i.e., GAGE-1,2; Van den Eynde et al., J. Exp.
Med., 182:689-698 (1995); U.S. Pat. No. 6,013,765), RAGE family
antigens (i.e., RAGE-1; Gaugler et at., Immunogenetics, 44:323-330
(1996); U.S. Pat. No. 5,939,526), N-acetylglucosaminyltransferase-V
(Guilloux et at., J. Exp. Med., 183:1173-1183 (1996)), p15 (Robbins
et al., J. Immunol. 154:5944-5950 (1995)), .beta.-catenin (Robbins
et al., J. Exp. Med., 183:1185-1192 (1996)), MUM-1 (Coulie et al.,
Proc. Natl. Acad. Sci. USA, 92:7976-7980 (1995)), cyclin dependent
kinase-4 (CDK4) (Wolfel et al., Science, 269:1281-1284 (1995)),
p21-ras (Fossum et at., Int. J. Cancer, 56:40-45 (1994)), BCR-abl
(Bocchia et al., Blood, 85:2680-2684 (1995)), p53 (Theobald et al.,
Proc. Natl. Acad. Sci. USA, 92:11993-11997 (1995)), p185 HER2/neu
(erb-B1; Fisk et al., J. Exp. Med., 181:2109-2117 (1995)),
epidermal growth factor receptor (EGFR) (Harris et al., Breast
Cancer Res. Treat, 29:1-2 (1994)), carcinoembryonic antigens (CEA)
(Kwong et al., J. Natl. Cancer list., 85:982-990 (1995) U.S. Pat.
Nos. 5,756,103; 5,274,087; 5,571,710; 6,071,716; 5,698,530;
6,045,802; EP 263933; EP 346710; and, EP 784483);
carcinoma-associated mutated mucins (i.e., MUC-1 gene products;
Jerome et al., J. Immunol., 151:1654-1662 (1993)); EBNA gene
products of EBV (i.e., EBNA-1; Rickinson et al., Cancer Surveys,
13:53-80 (1992)); E7, E6 proteins of human papillomavirus (Ressing
et al., J. Immunol, 154:5934-5943 (1995)); prostate specific
antigen (PSA; Xue et al., The Prostate, 30:73-78 (1997)); prostate
specific membrane antigen (PSMA; Israeli, et al., Cancer Res.,
54:1807-1811 (1994)); idiotypic epitopes or antigens, for example,
immunoglobulin idiotypes or T cell receptor idiotypes (Chen et al.,
J. Immunol., 153:4775-4787 (1994)); KSA (U.S. Pat. No. 5,348,887),
kinesin 2 (Dietz, et al. Biochem Biophys Res Commun 2000 Sep.
7;275(3):731-8), HIP-55, TGF.beta.-1 anti-apoptotic factor (Toomey,
et al. Br J Biomed Sci 2001;58(3): 177-83), tumor protein D52
(Bryne J. A., et al., Genomics, 35:523-532 (1996)), H1FT, NY-BR-1
(WO 01/47959), NY-BR-62, NY-BR-75, NY-BR-85, NY-BR-87, NY-BR-96
(Scanlan, M. Serologic and Bioinformatic Approaches to the
Identification of Human Tumor Antigens, in Cancer Vaccines 2000,
Cancer Research Institute, New York, N.Y.), BFA4 (SEQ ID NOS.: 1
and 2), BCY1 (SEQ ID NOS.: 3 and 4), and BFA5 (SEQ ID NOS.: 5 and
6) including "wild-type" (i.e., normally encoded by the genome,
naturally-occurring), modified, and mutated versions as well as
other fragments and derivatives thereof. Any of these TAs may be
utilized alone or in combination with one another in a
co-immunization protocol.
[0016] In certain cases, it may be beneficial to co-immunize
patients with both TA and other antigens, such as
angiogeniesis-associated antigens ("AA"). An AA is an immunogenic
molecule (i.e., peptide, polypeptide) associated with cells
involved in the induction and/or continued development of blood
vessels. For example, an AA may be expressed on an endothelial cell
("EC"), which is a primary structural component of blood vessels.
For treatment of cancer, it is preferred that that the AA be found
within or near blood vessels that supply a tumor. Immunization of a
patient against an AA preferably results in an anti-AA immune
response whereby angiogenic processes that occur near or within
tumors are prevented and/or inhibited.
[0017] Exemplary AAs include, for example, vascular endothelial
growth factor (i.e., VEGF; Bernardini, et al., J. Urol., 2001,
166(4): 1275-9; Starnes, et al., J. Thorac. Cardiovasc. Surg.,
2001, 122(3): 518-23; Dias, et al., Blood, 2002, 99: 2179-2184),
the VEGF receptor (i.e., VEGF-R, flk-1/KDR; Starnes, et al. J.
Thorac. Cardiovasc. Surg., 2001, 122(3): 518-23), EPH receptors
(i.e., EPHA2; Gerety, et al. 1999, Cell, 4: 403-414), epidermal
growth factor receptor (i.e., EGFR; Ciardeillo, et al. Clin. Cancer
Res., 2001, 7(10): 2958-70), basic fibroblast growth factor (i.e.,
bFGF; Davidson, et al. Clin. Exp. Metastasis 2000,18(6): 501-7;
Poon, et al. Am J. Surg., 2001, 182(3):298-304), platelet-derived
cell growth factor (i.e., PDGF-B), platelet-derived endothelial
cell growth factor (PD-ECGF; Hong, et al. J. Mol. Med., 2001,
8(2):141-8), transforming growth factors (i.e., TGF-.alpha.; Hong,
et al. J. Mol. Med., 2001, 8(2):141-8), endoglin (Balza, et al.
Int. J Cancer, 2001, 94: 579-585), Id proteins (Benezra, R. Trends
Cardiovasc. Med., 2001, 11(6):237-41), proteases such as uPA, uPAR,
and matrix metalloproteinases (MMP-2, MMP-9; Djonov, et al. J.
Pathol., 2001, 195(2):147-55), nitric oxide synthase (Am. J.
Ophthalmol., 2001, 132(4):551-6), aminopeptidase (Rouslhati, E.
Nature Cancer, 2: 84-90, 2002), thrombosponidinis (i.e., TSP-1,
TSP-2; Alvarez, et al. Gynecol. Oncol., 2001, 82(2):273-8; Seki, et
al. Int. J. Oncol., 2001, 19(2):305-10), k-ras (Zhang, et al.
Cancer Res., 2001, 61(16):6050-4), Wnt (Zhanig, et al. Cancer Res.,
2001, 61(16):6050-4), cyclin-dependent kinases (CDKs; Drug Resist.
Updat. 2000, 3(2):83-88), microtubules (Timar, et al. 2001. Path.
Oncol. Res., 7(2): 85-94), heat shock proteins (i.e., HSP90 (Timar,
supra)), heparin-binding factors (i.e., heparinase; Gohji, et al.
Int. J. Cancer, 2001, 95(5):295-301), synthases (i.e., ATP
synthase, thymidilate synthase), collagen receptors, integrins
(i.e., .alpha..nu..beta.3, .alpha..nu..beta.5, .alpha..nu..beta.1,
.alpha.2.beta.1, .alpha.5.beta.1), the surface proteolglycan NG2,
AAC2-1 (SEQ ID NO.:1), or AAC.sub.2-2 (SEQ ID NO.:2), among others,
including "wild-type" (i.e., normally encoded by the genome,
naturally-occurring), modified, mutated versions as well as other
fragments and derivatives thereof. Any of these targets may be
suitable in practicing the present invention, either alone or in
combination with one another or with other agents.
[0018] In certain embodiments, a nucleic acid molecule encoding an
immunogenic target is utilized. The nucleic acid molecule may
comprise or consist of a nucleotide sequence encoding one or more
immunogenic targets, or fragments or derivatives thereof, such as
that contained in a DNA insert in an ATCC Deposit. The term
"nucleic acid sequence" or "nucleic acid molecule" refers to a DNA
or RNA sequence. The term encompasses molecules formed from any of
the known base analogs of DNA and RNA such as, but not limited to
4-acetylcytosine, 8-hydroxy-N-6-methyladenosine,
aziridinyl-cytosine, pseudoisocytosine, 5-(carboxyhydroxylmethyl)
uracil, 5-fluorouracil, 5-bromouracil,
5-carboxymethylaminomethyl-2-thiouracil,
5-carboxy-methylaminomethyluraci- l, dihydrouracil, inosine,
N6-iso-pentenyladenine, 1-methyladenine, 1-methylpseudouracil,
1-methylguanine, 1-methylinosine, 2,2-dimethyl-guanine,
2-methyladenine, 2-methylguanine, 3-methylcytosine,
5-methylcytosine, N6-methyladeninie, 7-methylguanine,
5-methylaminomethyluracil, 5-methoxyamino-methyl-2-thiouracil,
beta-D-mannosylqueosine, 5'-methoxycarbonyl-methyluracil,
5-methoxyuracil, 2-methylthio-N-6-isopentenyladenine,
uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid,
oxybutoxosine, pseudouracil, queosine, 2-thiocytosine,
5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil,
N-uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid,
pseudouracil, queosine, 2-thiocytosine, and 2,6-diaminopurine,
among others.
[0019] An isolated nucleic acid molecule is one that: (1) is
separated from at least about 50 percent of proteins, lipids,
carbohydrates, or other materials with which it is naturally found
when total nucleic acid is isolated from the source cells; (2) is
not linked to all or a portion of a polynucleotide to which the
nucleic acid molecule is linked in nature; (3) is operably linked
to a polynucleotide which it is not linked to in nature; and/or,
(4) does not occur in nature as part of a larger polynucleotide
sequence. Preferably, the isolated nucleic acid molecule of the
present invention is substantially free from any other
contaminating nucleic acid molecule(s) or other contaminants that
are found in its natural environment that would interfere with its
use in polypeptide production or its therapeutic, diagnostic,
prophylactic or research use. As used herein, the term "naturally
occurring" or "native" or "naturally found" when used in connection
with biological materials such as nucleic acid molecules,
polypeptides, host cells, and the like, refers to materials which
are found in nature Without manipulation by man. Similarly,
"non-naturally occurring" or "non-native" as used herein refers to
a material that is not found in nature or that has been
structurally modified or synthesized by man.
[0020] The identity of two or more nucleic acid or polypeptide
molecules is determined by comparing the sequences. As known in the
art, "identity" means the degree of sequence relatedness between
nucleic acid molecules or polypeptides as determined by the match
between the units making up the molecules (i.e., nucleotides or
amino acid residues). Identity measures the percent of identical
matches between the smaller of two or more sequences with gap
alignments (if any) addressed by a particular mathematical model or
computer program (i.e., an algorithm). Identity between nucleic
acid sequences may also be determined by the ability of the related
sequence to hybridize to the nucleic acid sequence or isolated
nucleic acid molecule. In defining such sequences, the term "highly
stringent conditions" and "moderately stringent conditions" refer
to procedures that permit hybridization of nucleic acid strands
whose sequences are complementary, and to exclude hybridization of
significantly mismatched nucleic acids. Examples of "highly
stringent conditions" for hybridization and washing are 0.015 M
sodium chloride, 0.0015 M sodium citrate at 65-68.degree. C. or
0.015 M sodium chloride, 0.0015 M sodium citrate, and 50% formamide
at 42.degree. C. (see, for example, Sambrook, Fritsch &
Maniatis, Molecular Cloning: A Laboratory Manual (2nd ed., Cold
Spring Harbor Laboratory, 1989); Anderson et al., Nucleic Acid
Hybridization: A Practical Approach Ch. 4 (IRL Press Limited)). The
term "moderately stringent conditions" refers to conditions under
which a DNA duplex with a greater degree of base pair mismatching
than could occur under "highly stringent conditions" is able to
form. Exemplary moderately stringent conditions are 0.015 M sodium
chloride, 0.0015 M sodium citrate at 50-65.degree. C. or 0.015 M
sodium chloride, 0.0015 M sodium citrate, and 20% formamide at
37-50.degree. C. By way of example, moderately stringent conditions
of 50.degree. C. in 0.015 M sodium ion will allow about a 21%
mismatch. During hybridization, other agents may be included in the
hybridization and washing buffers for the purpose of reducing
non-specific and/or background hybridization. Examples are 0.1%
bovine serum albumin, 0.1% polyvinyl-pyrrolidone, 0.1% sodium
pyrophosphate, 0.1% sodium dodecylsulfate, NaDodSO.sub.4, (SDS),
ficoll, Denhardt's solution, sonicated salmon sperm DNA (or another
non-complementary DNA), and dextran sulfate, although other
suitable agents can also be used. The concentration and types of
these additives can be changed without substantially affecting the
stringency of the hybridization conditions. Hybridization
experiments are usually carried out at pH 6.8-7.4; however, at
typical ionic strength conditions, the rate of hybridization is
nearly independent of pH.
[0021] In certain embodiments of the present invention, vectors are
used to transfer a nucleic acid sequence encoding a polypeptide to
a cell. A vector is any molecule used to transfer a nucleic acid
sequence to a host cell. In certain cases, an expression vector is
utilized. An expression vector is a nucleic acid molecule that is
suitable for transformation of a host cell and contains nucleic
acid sequences that direct and/or control the expression of the
transferred nucleic acid sequences. Expression includes, but is not
limited to, processes such as transcription, translation, and
splicing, if introns are present. Expression vectors typically
comprise one or more flanking sequences operably linked to a
heterologous nucleic acid sequence encoding a polypeptide. Flanking
sequences may be homologous (i.e., from the same species and/or
strain as the host cell), heterologous (i.e., from a species other
than the host cell species or strain), hybrid (i.e., a combination
of flanking sequences from more than one source), or synthetic, for
example.
[0022] A flanking sequence is preferably capable of effecting the
replication, transcription and/or translation of the coding
sequence and is operably linked to a coding sequence. As used
herein, the term operably linked refers to a linkage of
polynucleotide elements in a functional relationship. For instance,
a promoter or enhancer is operably linked to a coding sequence if
it affects the transcription of the coding sequence. However, a
flanking sequence need not necessarily be contiguous with the
coding sequence, so long as it functions correctly. Thus, for
example, intervening untranslated yet transcribed sequences can be
present between a promoter sequence and the coding sequence and the
promoter sequence may still be considered operably linked to the
coding sequence. Similarly, an enhancer sequence may be located
upstream or downstream from the coding sequence and affect
transcription of the sequence.
[0023] In certain embodiments, it is preferred that the flanking
sequence is a transcriptional regulatory region that drives
high-level gene expression in the target cell. The transcriptional
regulatory region may comprise, for example, a promoter, enhancer,
silencer, repressor element, or combinations thereof. The
transcriptional regulatory region may be either constitutive,
tissue-specific, cell-type specific (i.e., the region is drives
higher levels of transcription in a one type of tissue or cell as
compared to another), or regulatable (i.e., responsive to
interaction with a compound). The source of a transcriptional
regulatory region may be any prokaryotic or eukaryotic organism,
any vertebrate or invertebrate organism, or any plant, provided
that the flanking sequence functions in a cell by causing
transcription of a nucleic acid within that cell. A wide variety of
transcriptional regulatory regions may be utilized in practicing
the present invention.
[0024] Suitable transcriptional regulatory regions include, for
example, the CMV promoter (i.e., the CMV-immediate early promoter);
promoters from eukaryotic genes (i.e. the estrogen-inducible
chicken ovalbumin gene, the interferon genies, the
gluco-corticoid-inducible tyrosine aminotransferase gene, and the
thymidine kinase genie); and the major early and late adenovirus
gene promoters; the SV40 early promoter region (Bernoist and
Chambon, 1981, Nature 290:304-10); the promoter contained in the 3'
long terminal repeat (LTR) of Rous sarcoma virus (RSV) (Yamamoto,
et al., 1980, Cell 22:787-97); the herpes simplex virus thymidine
kinase (HSV-TK) promoter (Wagner et al., 1981, Proc. Natl. Acad.
Sci. U.S.A. 78:1444-45); the regulatory sequences of the
metallothionine gene (Brinster et al., 1982, Nature 296:39-42);
prokaryotic expression vectors such as the beta-lactamase promoter
(Villa-Kamaroff et al., 1978, Proc. Natl. Acad. Sci. U.S.A.,
75:3727-31); or the tac promoter (DeBoer et al., 1983, Proc. Natl.
Acad. Sci. U.S.A., 80:21-25). Tissue- and/or cell-type specific
transcriptional control regions include, for example, the elastase
I gene control region which is active in pancreatic acinar cells
(Swift et al., 1984, Cell 38:639-46; Ornitz et al., 1986, Cold
Spring Harbor Symp. Quant. Biol. 50:399-409 (1986); MacDonald,
1987, Hepatology 7:425-515); the insulin gene control region which
is active in pancreatic beta cells (Hanahan, 1985, Nature
315:115-22); the immunoglobulin gene control region which is active
in lymphoid cells (Grosschedl et al., 1984, Cell 38:647-58; Adames
et al., 1985, Nature 318:533-38; Alexander et al., 1987, Mol. Cell.
Biol., 7:1436-44); the mouse mammary tumor virus control region in
testicular, breast, lymphoid and mast cells (Leder et al., 1986,
Cell 45:485-95); the albumin gene control region in liver (Pinkert
et al., 1987, Genes and Devel. 1:268-76); the alpha-feto-protein
gene control region in liver (Krumlauf et al., 1985, Mol. Cell.
Biol., 5:1639-48; Hammer et al., 1987, Science 235:53-58); the
alpha 1-antitrypsin gene control region in liver (Kelsey et al.,
1987, Genes and Devel. 1:161-71); the beta-globin gene control
region in myeloid cells (Mogram et al., 1985, Nature 315:338-40;
Kollias et al., 1986, Cell 46:89-94); the myelin basic protein gene
control region in oligodendrocyte cells in the brain (Readhead et
al., 1987, Cell 48:703-12); the myosin light chain-2 gene control
region in skeletal muscle (Sani, 1985, Nature 314:283-86); the
gonadotropic releasing hormone gene control region in the
hypothalamus (Mason et al., 1986, Science 234:1372-78), and the
tyrosinase promoter in melanoma cells (Hart, 1. Semin Oncol 1996
February;23(1):154-8; Siders, et al. Cancer Gene Ther 1998
September-October;5(5):281-91), among others. Inducible promoters
that are activated in the presence of a certain compound or
condition such as light, heat, radiation, tetracycline, or heat
shock proteins, for example, may also be utilized (see, for
example, WO 00/10612). Other suitable promoters are known in the
art.
[0025] As described above, enhancers may also be suitable flanking
sequences. Enhancers are cis-acting elements of DNA, usually about
10-300 bp in length, that act on the promoter to increase
transcription. Enhancers are typically orientation- and
position-independent, having been identified both 5' and 3' to
controlled coding sequences. Several enhancer sequences available
from mammalian genes are known (i.e., globin, elastase, albumin,
alpha-feto-protein and insulin). Similarly, the SV40 enhancer, the
cytomegalovirus early promoter enhancer, the polyoma enhancer, and
adenovirus enhancers are useful with eukaryotic promoter sequences.
While an enhancer may be spliced into the vector at a position 5'
or 3' to nucleic acid coding sequence, it is typically located at a
site 5' from the promoter. Other suitable enhancers are known in
the art, and would be applicable to the present invention.
[0026] While preparing reagents of the present invention, cells may
need to be transfected or transformed. Transfection refers to the
uptake of foreign or exogenous DNA by a cell, and a cell has been
transfected when the exogenous DNA has been introduced inside the
cell membrane. A number of transfection techniques are well known
in the art (i.e., Graham et al., 1973, Virology 52:456; Sambrook et
al., Molecular Cloning, A Laboratory Manual (Cold Spring Harbor
Laboratories, 1989); Davis et al., Basic Methods in Molecular
Biology (Elsevier, 1986); and Chu et al., 1981, Gene 13:197). Such
techniques can be used to introduce one or more exogenous DNA
moieties into suitable host cells.
[0027] In certain embodiments, it is preferred that transfection of
a cell results in transformation of that cell. A cell is
transformed when there is a change in a characteristic of the cell,
being transformed when it has been modified to contain a new
nucleic acid. Following transfection, the transfected nucleic acid
may recombine with that of the cell by physically integrating into
a chromosome of the cell, may be maintained transiently as an
episomal element without being replicated, or may replicate
independently as a plasmid. A cell is stably transformed when the
nucleic acid is replicated with the division of the cell.
[0028] The present invention further provides isolated immunogenic
targets in polypeptide form. A polypeptide is considered isolated
where it: (1) has been separated from at least about 50 percent of
polynucleotides, lipids, carbohydrates, or other materials with
which it is naturally found when isolated from the source cell; (2)
is not linked (by covalent or noncovalent interaction) to all or a
portion of a polypeptide to which the "isolated polypeptide" is
linked in nature; (3) is operably linked (by covalent or
noncovalent interaction) to a polypeptide with which it is not
linked in nature; or, (4) does not occur in nature. Preferably, the
isolated polypeptide is substantially free from any other
contaminating polypeptides or other contaminants that are found in
its natural environment that would interfere with its therapeutic,
diagnostic, prophylactic or research use.
[0029] Immunogenic target polypeptides may be mature polypeptides,
as defined herein, and may or may not have an amino terminal
methionine residue, depending on the method by which they are
prepared. Further contemplated are related polypeptides such as,
for example, fragments, variants (i.e., allelic, splice),
orthologs, homologues, and derivatives, for example, that possess
at least one characteristic or activity (i.e., activity,
antigenicity) of the immunogenic target. Also related are peptides,
which refers to a series of contiguous amino acid residues having a
sequence corresponding to at least a portion of the polypeptide
from which its sequence is derived. In preferred embodiments, the
peptide comprises about 5-10 amino acids, 10-15 amino acids, 15-20
amino acids, 20-30 amino acids, or 30-50 amino acids. In a more
preferred embodiment, a peptide comprises 9-12 amino acids,
suitable for presentation upon Class I MHC molecules, for
example.
[0030] A fragment of a nucleic acid or polypeptide comprises a
truncation of the sequence (i.e., nucleic acid or polypeptide) at
the amino terminus (with or without a leader sequence) and/or the
carboxy terminus. Fragments may also include variants (i.e.,
allelic, splice), orthologs, homologues, and other variants having
one or more amino acid additions or substitutions or internal
deletions as compared to the parental sequence. In preferred
embodiments, truncations and/or deletions comprise about 10 amino
acids, 20 amino acids, 30 amino acids, 40 amino acids, 50 amino
acids, or more. The polypeptide fragments so produced will comprise
about 10 amino acids, 25 amino acids, 30 amino acids, 40 amino
acids, 50 amino acids, 60 amino acids, 70 amino acids, or more.
Such polypeptide fragments may optionally comprise an amino
terminal methionine residue. It will be appreciated that such
fragments can be used, for example, to generate antibodies or
cellular immune responses to immunogenic target polypeptides.
[0031] A variant is a sequence having one or more sequence
substitutions, deletions, and/or additions as compared to the
subject sequence. Variants may be naturally occurring or
artificially constructed. Such variants may be prepared from the
corresponding nucleic acid molecules. In preferred embodiments, the
variants have from 1 to 3, or from 1 to 5, or from 1 to 10, or from
1 to 15, or from 1 to 20, or from 1 to 25, or from 1 to 30, or from
1 to 40, or from 1 to 50, or more than 50 amino acid substitutions,
insertions, additions and/or deletions.
[0032] An allelic variant is one of several possible
naturally-occurring alternate forms of a gene occupying a given
locus on a chromosome of an organism or a population of organisms.
A splice variant is a polypeptide generated from one of several RNA
transcript resulting from splicing of a primary transcript. An
ortholog is a similar nucleic acid or polypeptide sequence from
another species. For example, the mouse and human versions of an
immunogenic target polypeptide may be considered orthologs of each
other. A derivative of a sequence is one that is derived from a
parental sequence those sequences having substitutions, additions,
deletions, or chemically modified variants. Variants may also
include fusion proteins, which refers to the fusion of one or more
first sequences (such as a peptide) at the amino or carboxy
terminus of at least one other sequence (such as a heterologous
peptide).
[0033] "Similarity" is a concept related to identity, except that
similarity refers to a measure of relatedness which includes both
identical matches and conservative substitution matches. If two
polypeptide sequences have, for example, 10/20 identical amino
acids, and the remainder are all non-conservative substitutions,
then the percent identity and similarity would both be 50%. If in
the same example, there are five more positions where there are
conservative substitutions, then the percent identity remains 50%,
but the percent similarity would be 75% (15/20). Therefore, in
cases where there are conservative substitutions, the percent
similarity between two polypeptides will be higher than the percent
identity between those two polypeptides.
[0034] Substitutions may be conservative, or non-conservative, or
any combination thereof. Conservative amino acid modifications to
the sequence of a polypeptide (and the corresponding modifications
to the encoding nucleotides) may produce polypeptides having
functional and chemical characteristics similar to those of a
parental polypeptide. For example, a "conservative amino acid
substitution" may involve a substitution of a native amino acid
residue with a non-native residue such that there is little or no
effect on the size, polarity, charge, hydrophobicity, or
hydrophilicity of the amino acid residue at that position and, in
particular, does not result in decreased immunogenicity. Suitable
conservative amino acid substitutions are shown in Table I.
1TABLE I Original Preferred Residues Exemplary Substitutions
Substitutions Ala Val, Leu, Ile Val Arg Lys, Gln, Asn Lys Asn Gln
Gln Asp Glu Glu Cys Ser, Ala Ser Gln Asn Asn Glu Asp Asp Gly Pro,
Ala Ala His Asn, Gln, Lys, Arg Arg Ile Leu, Val, Met, Ala, Phe, Leu
Norleucine Leu Norleucine, Ile, Val, Met, Ile Ala, Phe Lys Arg, 1,4
Diamino-butyric Arg Acid, Gln, Asn Met Leu, Phe, Ile Leu Phe Leu,
Val, Ile, Ala, Tyr Leu Pro Ala Gly Ser Thr, Ala, Cys Thr Thr Ser
Ser Trp Tyr, Phe Tyr Tyr Trp, Phe, Thr, Ser Phe Val Ile, Met, Leu,
Phe, Ala, Leu Norleucine
[0035] A skilled artisan will be able to determine suitable
variants of polypeptide using well-known techniques. For
identifying suitable areas of the molecule that may be changed
without destroying biological activity (i.e., MHC binding,
immunogenicity), one skilled in the art may target areas not
believed to be important for that activity. For example, when
similar polypeptides with similar activities from the same species
or from other species are known, one skilled in the art may compare
the amino acid sequence of a polypeptide to such similar
polypeptides. By performing such analyses, one can identify
residues and portions of the molecules that are conserved among
similar polypeptides. It will be appreciated that changes in areas
of the molecule that are not conserved relative to such similar
polypeptides would be less likely to adversely affect the
biological activity and/or structure of a polypeptide. Similarly,
the residues required for binding to MHC are known, and may be
modified to improve binding. However, modifications resulting in
decreased binding to MHC will not be appropriate in most
situations. One skilled in the art would also know that, even in
relatively conserved regions, one may substitute chemically similar
amino acids for the naturally occurring residues while retaining
activity. Therefore, even areas that may be important for
biological activity or for structure may be subject to conservative
amino acid substitutions without destroying the biological activity
or without adversely affecting the polypeptide structure.
[0036] Other preferred polypeptide variants include glycosylation
variants wherein the number and/or type of glycosylation sites have
been altered compared to the subject amino acid sequence. In one
embodiment, polypeptide variants comprise a greater or a lesser
number of N-linked glycosylation sites than the subject amino acid
sequence. An N-linked glycosylation site is characterized by the
sequence Asn-X-Ser or Asn-X-Thr, wherein the amino acid residue
designated as X may be any amino acid residue except proline. The
substitution of amino acid residues to create this sequence
provides a potential new site for the addition of an N-linked
carbohydrate chain. Alternatively, substitutions that eliminate
this sequence will remove an existing N-linked carbohydrate chain.
Also provided is a rearrangement of N-linked carbohydrate chains
wherein one or more N-linked glycosylation sites (typically those
that are naturally occurring) are eliminated and one or more new
N-linked sites are created. To affect O-linked glycosylation of a
polypeptide, one would modify serine and/or threonine residues.
[0037] Additional preferred variants include cysteine variants,
wherein one or more cysteine residues are deleted or substituted
with another amino acid (e.g., serine) as compared to the subject
amino acid sequence set. Cysteine variants are useful when
polypeptides must be refolded into a biologically active
conformation such as after the isolation of insoluble inclusion
bodies. Cysteine variants generally have fewer cysteine residues
than the native protein, and typically have an even number to
minimize interactions resulting from unpaired cysteines.
[0038] In other embodiments, the isolated polypeptides of the
current invention include fusion polypeptide segments that assist
in purification of the polypeptides. Fusions can be made either at
the amino terminus or at the carboxy terminus of the subject
polypeptide variant thereof. Fusions may be direct with no linker
or adapter molecule or may be through a linker or adapter molecule.
A linker or adapter molecule may be one or more amino acid
residues, typically from about 20 to about 50 amino acid residues.
A linker or adapter molecule may also be designed with a cleavage
site for a DNA restriction endonuclease or for a protease to allow
for the separation of the fused moieties. It will be appreciated
that once constructed, the fusion polypeptides can be derivatized
according to the methods described herein. Suitable fusion segments
include, among others, metal binding domains (e.g., a
poly-histidine segment), immunoglobulin binding domains (i.e.,
Protein A, Protein G, T cell, B cell, Fc receptor, or complement
protein antibody-binding domains), sugar binding domains (e.g., a
maltose binding domain), and/or a "tag" domain (i.e., at least a
portion of .alpha.-galactosidase, a strep tag peptide, a T7 tag
peptide, a FLAG peptide, or other domains that can be purified
using compounds that bind to the domain, such as monoclonal
antibodies). This tag is typically fused to the polypeptide upon
expression of the polypeptide, and can serve as a means for
affinity purification of the sequence of interest polypeptide from
the host cell. Affinity purification can be accomplished, for
example, by column chromatography using antibodies against the tag
as an affinity matrix. Optionally, the tag can subsequently be
removed from the purified sequence of interest polypeptide by
various means such as using certain peptidases for cleavage. As
described below, fusions may also be made between a TA and a
co-stimulatory components such as the chemokines CXC10 (IP-10),
CCL7 (MCP-3), or CCL5 (RANTES), for example.
[0039] A fusion motif may enhance transport of an immunogenic
target to an MHC processing compartment, such as the endoplasmic
reticulum. These sequences, referred to as tranduction or
transcytosis sequences, include sequences derived from HIV tat (see
Kim et al. 1997 J. Immunol. 159:1666), Drosophila antennapedia (see
Schutze-Redelmeier et al. 1996 J. Immunol. 157:650), or human
period-1 protein (hPER1; in particular, SRRHHCRSKAKRSRHH).
[0040] In addition, the polypeptide or variant thereof may be fused
to a homologous polypeptide to form a homodimer or to a
heterologous polypeptide to form a heterodimer. Heterologous
peptides and polypeptides include, but are not limited to: an
epitope to allow for the detection and/or isolation of a fusion
polypeptide; a transmembrane receptor protein or a portion thereof,
such as an extracellular domain or a transmembrane and
intracellular domain; a ligand or a portion thereof which binds to
a transmembrane receptor protein; an enzyme or portion thereof
which is catalytically active; a polypeptide or peptide which
promotes oligomerization, such as a leucine zipper domain; a
polypeptide or peptide which increases stability, such as an
immunoglobulin constant region; and a polypeptide which has a
therapeutic activity different from the polypeptide or variant
thereof.
[0041] In certain embodiments, it may be advantageous to combine a
nucleic acid sequence encoding an immunogenic target, polypeptide,
or derivative thereof with one or more nucleic acid sequences
encoding one or more co-stimulatory component(s) such as cell
surface proteins, cytokines or chemokines in a composition of the
present invention. The co-stimulatory component may be included in
the composition as a polypeptide or as a nucleic acid encoding the
polypeptide, for example. Suitable co-stimulatory molecules
include, for instance, polypeptides that bind members of the CD28
family (i.e., CD28, ICOS; Hutloff, et al. Nature 1999, 397:
263-265; Peach, et al. J Exp Med 1994, 180: 2049-2058) such as the
CD28 binding polypeptides B7.1 (CD80; Schwartz, 1992; Chen et al,
1992; Ellis, et al. J. Immunol., 156(8): 2700-9) and B7.2 (CD86;
Ellis, et al. J. Immunol., 156(8): 2700-9); mutated and derivative
B7 molecules (WO 00/66162); polypeptides which bind members of the
integrin family (i.e., LFA-1 (CD11a/CD18); Sedwick, et al. J
Immunol 1999, 162: 1367-1375; Wulfing, et al. Science 1998, 282:
2266-2269; Lub, et al. Immunol Today 1995, 16: 479-483) including
members of the ICAM family (i.e., ICAM-1, -2 or -3); polypeptides
which bind CD2 family members (i.e., CD2, signalling lymphocyte
activation molecule (CDw150 or "SLAM"; Aversa, et al. J Immunol
1997, 158: 4036-4044)) such as CD58 (LFA-3; CD2 ligand; Davis, et
al. Immunol Today 1996, 17: 177-187) or SLAM ligands (Sayos, et al.
Nature 1998, 395: 462-469); polypeptides which bind heat stable
antigen (HSA or CD24; Zhou, et al. Eur J Immunol 1997, 27:
2524-2528); polypeptides which bind to members of the TNF receptor
(TNFR) family (i.e., 4-1BB (CD137; Vinay, et al. Semin Immunol
1998, 10: 481-489), OX40 (CD134; Weinberg, et al. Semin Immunol
1998, 10: 471-480; Higgins, et al. J Immunol 1999, 162: 486-493),
and CD27 (Lens, et al. Semin Immunol 1998, 10: 491-499)) such as
4-1BBL (4-1BB ligand; Vinay, et al. Semin Immunol 1998, 10: 481-48;
DeBenedette, et al. J Immunol 1997, 158: 551-559), TNFR associated
factor-1 (TRAF-1; 4-1BB ligand; Saoulli, et al. J Exp Med 1998,
187: 1849-1862, Arch, et al. Mol Cell Biol 1998, 18: 558-565),
TRAF-2 (4-1BB and OX40 ligand; Saoulli, et al. J Exp Med 1998, 187:
1849-1862; Oshima, et al. Int Immunol 1998, 10: 517-526, Kawamata,
et al. J Biol Chem 1998, 273: 5808-5814), TRAF-3 (4-1BB and OX40
ligand; Arch, et al. Mol Cell Biol 1998, 18: 558-565; Jang, et al.
Biochem Biophys Res Commun 1998, 242: 613-620; Kawamata S, et al. J
Biol Chem 1998, 273: 5808-5814), OX40L (OX40 ligand; Gramaglia, et
al. J Immunol 1998, 161: 6510-6517), TRAF-5 (OX40 ligand; Arch, et
al. Mol Cell Biol 1998, 18: 558-565; Kawainata, et al. J Biol Chem
1998, 273: 5808-5814), and CD70 (CD27 ligand; Couderc, et al.
Cancer Gene Ther., 5(3): 163-75). CD154 (CD40 ligand or "CD40L";
Gurunathan, et al. J. Immunol., 1998, 161: 4563-4571; Sine, et al.
Hum. Gene Ther., 2001, 12: 1091-1102) may also be suitable.
[0042] One or more cytokines may also be suitable co-stimulatory
components or "adjuvants", either as polypeptides or being encoded
by nucleic acids contained within the compositions of the present
invention (Painiani, et al. Immunol Lett 2000 Sep. 15; 74(1): 41-4;
Berzofsky, et al. Nature Immunol. 1: 209-219). Suitable cytokines
include, for example, interleukin-2 (IL-2) (Rosenberg, et al.
Nature Med. 4: 321-327 (1998)), IL-4, IL-7, IL-12 (reviewed by
Pardoll, 1992; Harries, et al. J. Gene Med. 2000
July-August;2(4):243-9; Rao, et al. J. Immunol. 156: 3357-3365
(1996)), IL-15 (Xin, et al. Vaccine, 17:858-866, 1999), IL-16
(Cruikshank, et al. J. Leuk Biol. 67(6): 757-66, 2000), IL-18 (J.
Cancer Res. Clin. Oncol. 2001. 127(12): 718-726), GM-CSF (CSF
(Disis, et al. Blood, 88: 202-210 (1996)), tumor necrosis
factor-alpha (TNF-.alpha.), or interferons such as IFN-.alpha. or
INF-.gamma.. Other cytokines may also be suitable for practicing
the present invention, as is known in the art.
[0043] Chemokines may also be utilized. For example, fusion
proteins comprising CXCL10 (IP-10) and CCL7 (MCP-3) fused to a
tumor self-antigen have been shown to induce anti-tumor immunity
(Biragyn, et al. Nature Biotech. 1999, 17: 253-258). The chemokines
CCL3 (MIP-1.alpha.) and CCL5 (RANTES) (Boyer, et al. Vaccine, 1999,
17 (Supp. 2): S53-S64) may also be of use in practicing the present
invention. Other suitable chemokines are known in the art.
[0044] It is also known in the art that suppressive or negative
regulatory immune mechanisms may be blocked, resulting in enhanced
immune responses. For instance, treatment with anti-CTLA-4
(Shrikant, et al. Immunity, 1996, 14: 145-155; Sutmuller, et al. J.
Exp. Med., 2001, 194: 823-832), anti-CD25 (Sutmuller, supra),
anti-CD4 (Matsui, et al. J. Immunol., 1999, 163: 184-193), the
fusion protein IL13Ra2-Fc (Terabe, et al. Nature Immunol., 2000, 1:
515-520), and combinations thereof (i.e., anti-CTLA-4 and
anti-CD25, Sutmuller, supra) have been shown to upregulate
anti-tumor immune responses and would be suitable in practicing the
present invention.
[0045] Any of these components may be used alone or in combination
with other agents. For instance, it has been shown that a
combination of CD80, ICAM-1 and LFA-3 ("TRICOM") may potentiate
anti-cancer immune responses (Hodge, et al. Cancer Res. 59:
5800-5807 (1999). Other effective combinations include, for
example, IL-12+GM-CSF (Ahlers, et al. J. Immunol., 158: 3947-3958
(1997); Iwasaki, et al. J. Immunol. 158: 4591-4601 (1997)),
IL-12+GM-CSF+TNF-.alpha. (Ahlers, et al. Int. Immunol. 13: 897-908
(2001)), CD80+IL-12 (Fruend, et al. Int. J. Cancer, 85: 508-517
(2000); Rao, et al. supra), and CD86+GM-CSF+IL-12 (Iwasaki, supra).
One of skill in the art would be aware of additional combinations
useful in carrying out the present invention. In addition, the
skilled artisan would be aware of additional reagents or methods
that may be used to modulate such mechanisms. These reagents and
methods, as well as others known by those of skill in the art, may
be utilized in practicing the present invention.
[0046] Additional strategies for improving the efficiency of
nucleic acid-based immunization may also be used including, for
example, the use of self-replicating viral replicons (Caley, et al.
1999. Vaccine, 17: 3124-2135; Dubensky, et al. 2000. Mol. Med. 6:
723-732; Leitner, et al. 2000. Cancer Res. 60: 51-55), codon
optimization (Liu, et al. 2000. Mol. Ther., 1: 497-500; Dubensky,
supra; Huang, et al. 2001. J. Virol. 75: 4947-4951), in vivo
electroporation (Widera, et al. 2000. J. Immunol. 164: 4635-3640),
incorporation of CpG stimulatory motifs (Gurunathan, et al. Ann.
Rev. Immunol., 2000, 18: 927-974; Leitner, supra; Cho, et al. J.
Immunol. 168(10):4907-13), sequences for targeting of the endocytic
or ubiquitin-processing pathways (Thomson, et al. 1998. J. Virol.
72: 2246-2252; Velders, et al. 2001. J. Immunol. 166: 5366-5373),
Marek's disease virus type 1 VP22 sequences (J. Virol.
76(6):2676-82, 2002), prime-boost regimens (Gurunathan, supra;
Sullivan, et al. 2000. Nature, 408: 605-609; Hanke, et al. 1998.
Vaccine, 16: 439-445; Amara, et al. 2001. Science, 292: 69-74), and
the use of mucosal delivery vectors such as Salmonella (Darji, et
al. 1997. Cell, 91: 765-775; Woo, et al. 2001. Vaccine, 19:
2945-2954). Other methods are known in the art, some of which are
described below.
[0047] Chemotherapeutic agents, radiation, anti-angiogenic
compounds, or other agents may also be utilized in treating and/or
preventing cancer using immunogenic targets (Sebti, et al. Oncogene
2000 Dec. 27;19(56):6566-73). For example, in treating metastatic
breast cancer, useful chemotherapeutic agents include
cyclophosphamide, doxorubicin, paclitaxel, docetaxel, navelbine,
capecitabine, and mitomycin C, among others. Combination
chemotherapeutic regimens have also proven effective including
cycloplhosphamide+methotrexate+5-fluorouracil;
cyclophosphamide+doxorubicin+5-fluorouracil; or,
cyclophosphamide+doxorub- icin, for example. Other compounds such
as prednisone, a taxane, navelbine, mitomycin C, or vinblastine
have been utilized for various reasons. A majority of breast cancer
patients have estrogen-receptor positive (ER+) tumors and in these
patients, endocrine therapy (i.e., tamoxifen) is preferred over
chemotherapy. For such patients, tamoxifen or, as a second line
therapy, progestins (medroxyprogesterone acetate or megestrol
acetate) are preferred. Aromatase inhibitors (i.e.,
aminoglutetlhimide and analogs thereof such as letrozole) decrease
the availability of estrogen needed to maintain tumor growth and
may be used as second or third line endocrine therapy in certain
patients.
[0048] Other cancers may require different chemotherapeutic
regimens. For example, metastatic colorectal cancer is typically
treated with Camptosar (irinotecan or CPT-11), 5-fluorouracil or
leucovorin, alone or in combination with one another. Proteinase
and integrin inhibitors such as as the MMP inhibitors marimastate
(British Biotech), COL-3 (Collagenex), Neovastat (Aeterna), AG3340
(Agouron), BMS-275291 (Bristol Myers Squibb), CGS 27023A (Novartis)
or the integrin inhibitors Vitaxin (Medimmune), or MED 1522 (Merck
KgaA) may also be suitable for use. As such, immunological
targeting of immunogenic targets associated with colorectal cancer
could be performed in combination with a treatment using those
chemotherapeutic agents. Similarly, chemotherapeutic agents used to
treat other types of cancers are well-known in the art and may be
combined with the immunogenic targets described herein.
[0049] Many anti-angiogenic agents are known in the art and would
be suitable for co-administration with the immunogenic target
vaccines (see, for example, Timar, et al. 2001. Pathology Oncol.
Res., 7(2): 85-94). Such agents include, for example, physiological
agents such as growth factors (i.e., ANG-2, NK1,2,4 (HGF),
transforming growth factor beta (TGF-.beta.)), cytokines (i.e.,
interferons such as IFN-.alpha., -.beta., -.gamma., platelet factor
4 (PF-4), PR-39), proteases (i.e., cleaved AT-III, collagen XVIII
fragment (Endostatin)), HmwKallikrein-d5 plasmin fragment
(Angiostatin), prothrombin-F1-2, TSP-1), protease inhibitors (i.e.,
tissue inhibitor of metalloproteases such as TIMP-1, -2, or -3;
maspin; plasminogen activator-inhibitors such as PAI-1; pigment
epithelium derived factor (PEDF)), Tumstatin (available through
ILEX, Inc.), antibody products (i.e., the collagen-binding
antibodies HUIV26, HU177, XL313; anti-VEGF; anti-integrin (i.e.,
Vitaxin, (Lxsys))), and glycosidases (i.e., heparinase-I, -III).
"Chemical" or modified physiological agents known or believed to
have anti-angiogenic potential include, for example, vinblastine,
taxol, ketoconazole, thalidomide, dolestatin, combrestatin A,
rapamycin (Guba, et al. 2002, Nature Med., 8: 128-135), CEP-7055
(available from Cephalon, Inc.), flavone acetic acid, Bay 12-9566
(Bayer Corp.), AG3340 (Agouron, Inc.), CGS 27023A (Novartis),
tetracylcine derivatives (i.e., COL-3 (Collagenix, Inc.)),
Neovastat (Aeterna), BMS-275291 (Bristol-Myers Squibb), low dose
5-FU, low dose methotrexate (MTX), irsofladine, radicicol,
cyclosporine, captopril, celecoxib, D45152-sulphated
polysaccharide, cationic protein (Protamine), cationic
peptide-VEGF, Suramin (polysulphonated napthyl urea), compounds
that interfere with the function or production of VEGF (i.e.,
SU5416 or SU6668 (Sugen), PTK787/ZK22584 (Novartis)), Distamycin A,
Angiozyme (ribozyme), isoflavinoids, staurosporine derivatives,
genistein, EMD121974 (Merck KcgaA), tyrphostins, isoquinolones,
retinoic acid, carboxyamidotriazole, TNP-470, octreotide,
2-methoxyestradiol, aminosterols (i.e., squalamine), glutathione
analogues (i.e., N-acteyl-L-cysteine), combretastatin A-4
(Oxigene), Eph receptor blocking agents (Nature, 414:933-938,
2001), Rh-Angiostatin, Rh-Endostatin (WO 01/93897), cyclic-RGD
peptide, accutin-disintegrini, benzodiazepenes, humanized anti-avb3
Ab, R1-PAI-2, amiloride, p-amidobenzamidine, anti-uPA ab, anti-uPAR
Ab, L-phanylalanin-N-methylamides (i.e., Batimistat, Marimastat),
AG3340, and minocycline. Many other suitable agents are known in
the art and would suffice in practicing the present invention.
[0050] The present invention may also be utilized in combination
with "non-traditional" methods of treating cancer. For example, it
has recently been demonstrated that administration of certain
anaerobic bacteria may assist in slowing tumor growth. In one
study, Clostridium novyi was modified to eliminate a toxin gene
carried on a phage episome and administered to mice with colorectal
tumors (Dang, et al. P.N.A.S. USA, 98(26): 15155-15160, 2001). In
combination with chemotherapy, the treatment was shown to cause
tumor necrosis in the animals. The reagents and methodologies
described in this application may be combined with such treatment
methodologies.
[0051] Nucleic acids encoding immunogenic targets may be
administered to patients by any of several available techniques.
Various viral vectors that have been successfully utilized for
introducing a nucleic acid to a host include retrovirus,
adenovirus, adeno-associated virus (AAV), herpes virus, and
poxvirus, among others. It is understood in the art that many such
viral vectors are available in the art. The vectors of the present
invention may be constructed using standard recombinant techniques
widely available to one skilled in the art. Such techniques may be
found in common molecular biology references such as Molecular
Cloning: A Laboratory Manual (Sambrook, et al., 1989, Cold Spring
Harbor Laboratory Press), Gene Expression Technology (Methods in
Enzymology, Vol. 185, edited by D. Goeddel, 1991. Academic Press,
San Diego, Calif.), and PCR Protocols: A Guide to Methods and
Applications (Innis, et al. 1990. Academic Press, San Diego,
Calif.).
[0052] Preferred retroviral vectors are derivatives of lentivirus
as well as derivatives of murine or avian retroviruses. Examples of
suitable retroviral vectors include, for example, Moloney murine
leukemia virus (MoMuLV), Harvey murine sarcoma virus (HaMuSV),
murine mammary tumor virus (MuMTV), SIV, BIV, HIV and Rous Sarcoma
Virus (RSV). A number of retroviral vectors can incorporate
multiple exogenous nucleic acid sequences. As recombinant
retroviruses are defective, they require assistance in order to
produce infectious vector particles. This assistance can be
provided by, for example, helper cell lines encoding retrovirus
structural genes. Suitable helper cell lines include .PSI.2, PA317
and PA12, among others. The vector virions produced using such cell
lines may then be used to infect a tissue cell line, such as NIH
3T3 cells, to produce large quantities of chimeric retroviral
virions. Retroviral vectors may be administered by traditional
methods (i.e., injection) or by implantation of a "producer cell
line" in proximity to the target cell population (Culver, K., et
al., 1994, Hum. Gene Ther., 5 (3): 343-79; Culver, K., et al., Cold
Spring Harb. Symp. Quant. Biol., 59: 685-90); Oldfield, E., 1993,
Hum. Gene Ther., 4 (1): 39-69). The producer cell line is
engineered to produce a viral vector and releases viral particles
in the vicinity of the target cell. A portion of the released viral
particles contact the target cells and infect those cells, thus
delivering a nucleic acid of the present invention to the target
cell. Following infection of the target cell, expression of the
nucleic acid of the vector occurs.
[0053] Adenoviral vectors have proven especially useful for gene
transfer into eukaryotic cells (Rosenfeld, M., et al., 1991,
Science, 252 (5004): 431-4; Crystal, R., et al., 1994, Nat. Genet.,
8 (1): 42-51), the study eukaryotic gene expression (Levrero, M.,
et al., 1991, Gene, 101 (2): 195-202), vaccine development (Graham,
F. and Prevec, L., 1992, Biotechnology, 20: 363-90), and in animal
models (Stratford-Perricaudet, L., et al., 1992, Bone Marrow
Transplant., 9 (Suppl. 1): 151-2; Rich, D., et al., 1993, Hum. Gene
Ther., 4 (4): 461-76). Experimental routes for administrating
recombinant Ad to different tissues in vivo have included
intratracheal instillation (Rosenfeld, M., et al., 1992, Cell, 68
(1): 143-55) injection into muscle (Quantin, B., et al., 1992,
Proc. Natl. Acad. Sci. U.S.A., 89 (7): 2581-4), peripheral
intravenous injection (Herz, J., and Gerard, R., 1993, Proc. Natl.
Acad. Sci. U.S.A., 90 (7): 2812-6) and stereotactic inoculation to
brain (Le Gal La Salle, G., et al., 1993, Science, 259 (5097):
988-90), among others.
[0054] Adeno-associated virus (AAV) demonstrates high-level
infectivity, broad host range and specificity in integrating into
the host cell genome (Hermonat, P., et al., 1984, Proc. Natl. Acad.
Sci. U.S.A., 81 (20): 6466-70). And Herpes Simplex Virus type-1
(HSV-1) is yet another attractive vector system, especially for use
in the nervous system because of its neurotropic property (Geller,
A., et al., 1991, Trends Neurosci., 14 (10): 428-32; Glorioso, et
al., 1995, Mol. Biotechnol., 4 (1): 87-99; Glorioso, et al., 1995,
Annu. Rev. Microbiol., 49: 675-710).
[0055] Poxvirus is another useful expression vector (Smith, et al.
1983, Gene, 25 (1): 21-8; Moss, et al, 1992, Biotechnology; 20:
345-62; Moss, et al, 1992, Curr. Top. Microbiol. Immunol., 158:
25-38; Moss, et al. 1991. Science, 252: 1662-1667). Poxviruses
shown to be useful include vaccinia, NYVAC, avipox, fowlpox,
canarypox, ALVAC, and ALVAC(2), among others.
[0056] NYVAC (vP866) was derived from the Copenhagen vaccine strain
of vaccinia virus by deleting six nonessential regions of the
genome encoding known or potential virulence factors (see, for
example, U.S. Pat. Nos. 5,364,773 and 5,494,807). The deletion loci
were also engineered as recipient loci for the insertion of foreign
genes. The deleted regions are: thymidine kinase gene (TK; J2R);
hemorrhagic region (u; B13R+B14R); A type inclusion body region
(ATI; A26L); hemagglutinin gene (HA; A56R); host range gene region
(C7L-K1L); and, large subunit, ribonucleotide reductase (14L).
NYVAC is a genetically engineered vaccinia virus strain that was
generated by the specific deletion of eighteen open reading frames
encoding gene products associated with virulence and host range.
NYVAC has been show to be useful for expressing TAs (see, for
example, U.S. Pat. No. 6,265,189). NYVAC (vP866), vP994, vCP205,
vCP1433, placZH6H4Lreverse, pMPC6H6K3E3 and pC3H.sub.6FHVB were
also deposited with the ATCC under the terms of the Budapest
Treaty, accession numbers VR-2559, VR-2558, VR-2557, VR-2556,
ATCC-97913, ATCC-97912, and ATCC-97914, respectively.
[0057] ALVAC-based recombinant viruses (i.e., ALVAC-1 and ALVAC-2)
are also suitable for use in practicing the present invention (see,
for example, U.S. Pat. No. 5,756,103). ALVAC(2) is identical to
ALVAC(1) except that ALVAC(2) genome comprises the vaccinia E3L and
K3L genes under the control of vaccinia promoters (U.S. Pat. No.
6,130,066; Beattie et al., 1995a, 1995b, 1991; Chang et al., 1992;
Davies et al., 1993). Both ALVAC(1) and ALVAC(2) have been
demonstrated to be useful in expressing foreign DNA sequences, such
as TAs (Tartaglia et al., 1993 a,b; U.S. Pat. No. 5,833,975). ALVAC
was deposited under the tenns of the Budapest Treaty with the
American Type Culture Collection (ATCC), 10801 University
Boulevard, Manassas, Va. 20110-2209, USA, ATCC accession number
VR-2547.
[0058] Another useful poxvirus vector is TROVAC. TROVAC refers to
an attenuated fowlpox that was a plaque-cloned isolate derived from
the FP-1 vaccine strain of fowlpoxvirus which is licensed for
vaccination of 1 day old chicks. TROVAC was likewise deposited
under the terms of the Budapest Treaty with the ATCC, accession
number 2553.
[0059] "Non-viral" plasmid vectors may also be suitable in
practicing the present invention. Preferred plasmid vectors are
compatible with bacterial, insect, and/or mammalian host cells.
Such vectors include, for example, PCR-II, pCR3, and pcDNA3.1
(Invitrogen, San Diego, Calif.), pBSII (Stratagene, La Jolla,
Calif.), pET15 (Novagen, Madison, Wis.), pGEX (Pharmacia Biotech,
Piscataway, N.J.), pEGFP-N2 (Clontech, Palo Alto, Calif.), pETL
(BlueBacII, Invitrogen), pDSR-alpha (PCT pub. No. WO 90/14363) and
pFastBacDual (Gibco-BRL, Grand Island, N.Y.) as well as
Bluescript.RTM. plasmid derivatives (a high copy number COLE1-based
phagemid, Stratagene Cloning Systems, La Jolla, Calif.), PCR
cloning plasmids designed for cloning Taq-amplified PCR products
(e.g., TOPO.TM. TA cloning.RTM. kit, PCR2.1.RTM. plasmid
derivatives, Invitrogen, Carlsbad, Calif.). Bacterial vectors may
also be used with the current invention. These vectors include, for
example, Shigella, Salmonella, Vibrio cholerae, Lactobacillus,
Bacille calmette gurin (BCG), and Streptococcus (see for example,
WO 88/6626; WO 90/0594; WO 91/13157; WO 92/1796; and WO 92/21376).
Many other non-viral plasmid expression vectors and systems are
known in the art and could be used with the current invention.
[0060] Suitable nucleic acid delivery techniques include DNA-ligand
complexes, adenovirus-ligand-DNA complexes, direct injection of
DNA, CaPO.sub.4 precipitation, gene gun techniques,
electroporation, and colloidal dispersion systems, among others.
Colloidal dispersion systems include macromolecule complexes,
nanocapsules, microspheres, beads, and lipid-based systems
including oil-in-water emulsions, micelles, mixed micelles, and
liposomes. The preferred colloidal system of this invention is a
liposome, which are artificial membrane vesicles useful as delivery
vehicles in vitro and in vivo. RNA, DNA and intact virions can be
encapsulated within the aqueous interior and be delivered to cells
in a biologically active form (Fraley, R., et al., 1981, Trends
Biochem. Sci., 6: 77). The composition of the liposome is usually a
combination of phospholipids, particularly
high-phase-transition-temperature phospholipids, usually in
combination with steroids, especially cholesterol. Other
phospholipids or other lipids may also be used. The physical
characteristics of liposomes depend on pH, ionic strength, and the
presence of divalent cations. Examples of lipids useful in liposome
production include phosphatidyl compounds, such as
phosphatidylglycerol, phosphatidylcholine, phosphatidylserine,
phosphatidylethanolamine, sphingolipids, cerebrosides, and
gangliosides. Particularly useful are diacylphosphatidylglycerols,
where the lipid moiety contains from 14-18 carbon atoms,
particularly from 16-18 carbon atoms, and is saturated.
Illustrative phospholipids include egg phosphatidylcholine,
dipalmitoylphosphatidylcholine and
distearoylphosphatidylcholine.
[0061] An immunogenic target may also be administer-ed in
combination with one or more adjuvants to boost the immune
response. Exemplary adjuvants are shown in Table II below:
2TABLE II Types of Immunologic Adjuvants Type of Adjuvant General
Examples Specific Examples/References Gel-type Aluminum
hydroxide/phosphate ("alum (Aggerbeck and Heron, 1995) adjuvants")
Calcium phosphate (Relyveld, 1986) Microbial Muramyl dipeptide
(MDP) (Chedid et al., 1986) Bacterial exotoxins Cholera toxin (CT),
E. coli labile toxin (LT)(Freytag and Clements, 1999)
Endotoxin-based adjuvants Monophosphoryl lipid A (MPL) (Ulrich and
Myers, 1995) Other bacterial CpG oligonucleotides (Corral and
Petray, 2000), BCG sequences (Krieg, et al. Nature, 374: 576),
tetanus toxoid (Rice, et al. J. Immunol., 2001, 167: 1558-1565)
Particulate Biodegradable (Gupta et al., 1998) Polymer microspheres
Immunostimulatory complexes (Morein and Bengtsson, 1999) (ISCOMs)
Liposomes (Wassef et al., 1994) Oil-emulsion Freund's incomplete
adjuvant (Jensen et al., 1998) and Microfluidized emulsions MF59
(Ott et al., 1995) surfactant- SAF (Allison and Byars, 1992) based
(Allison, 1999) adjuvants Saponins QS-21 (Kensil, 1996) Synthetic
Muramyl peptide derivatives Murabutide (Lederer, 1986) Threony-MDP
(Allison, 1997) Nonionic block copolymers L121 (Allison, 1999)
Polyphosphazene (PCPP) (Payne et al., 1995) Synthetic
polynucleotides Poly A:U, Poly I:C (Johnson, 1994) Thalidomide
derivatives CC-4047/ACTIMID (J. Immunol., 168(10): 4914-9)
[0062] The immunogenic targets of the present invention may also be
used to generate antibodies for use in screening assays or for
immunotherapy, which are another aspect of the present invention.
Other uses would be apparent to one of skill in the art. The term
"antibody" includes antibody fragments, as are known in the art,
including Fab, Fab.sub.2, single chain antibodies (Fv for example),
humanized antibodies, chimeric antibodies, human antibodies,
produced by several methods as are known in the art.
[0063] Methods of preparing and utilizing various types of
antibodies are well-known to those of skill in the art and would be
suitable in practicing the present invention (see, for example,
Harlow, et al. Antibodies: A Laboratory Manual, Cold Spring Harbor
Laboratory, 1988; Harlow, et al. Using Antibodies: A Laboratory
Manual, Portable Protocol No. 1, 1998; Kohler and Milstein, Nature,
256:495 (1975)); Jones et al. Nature, 321:522-525 (1986); Riechmann
et al. Nature, 332:323-329 (1988); Presta (Curr. Op. Struct. Biol.,
2:593-596 (1992); Verhoeyen et al. (Science, 239:1534-1536 (1988);
Hoogenboom et al., J. Mol. Biol., 227:381 (1991); Marks et al., J.
Mol. Biol., 222:581 (1991); Cole et al., Monoclonal Antibodies and
Cancer Therapy, Alan R. Liss, p. 77 (1985); Boerner et al., J.
Immunol., 147(1):86-95 (1991); Marks et al., Bio/Technology 10,
779-783 (1992); Lonberg et al., Nature 368 856-859 (1994);
Morrison, Nature 368 812-13 (1994); Fishwild et al., Nature
Biotechnology 14, 845-51 (1996); Neuberger, Nature Biotechnology
14, 826 (1996); Lonberg and Huszar, Intern. Rev. Immunol. 13 65-93
(1995); as well as U.S. Pat. Nos. 4,816,567; 5,545,807; 5,545,806;
5,569,825; 5,625,126; 5,633,425; and, 5,661,016). The antibodies or
derivatives therefrom may also be conjugated to therapeutic
moieties such as cytotoxic drugs or toxins, or active fragments
thereof such as diptheria A chain, exotoxin A chain, ricin A chain,
abrin A chain, curcin, crotin, phenomycin, enomycin, among others.
Cytotoxic agents may also include radiochemicals. Antibodies and
their derivatives may be incorporated into compositions of the
invention for use in vitro or in vivo.
[0064] Nucleic acids, proteins, or derivatives thereof representing
an immunogenic target may be used in assays to determine the
presence of a disease state in a patient, to predict prognosis, or
to determine the effectiveness of a chemotherapeutic or other
treatment regimen. Expression profiles, performed as is known in
the art, may be used to determine the relative level of expression
of the immunogenic target. The level of expression may then be
correlated with base levels to determine whether a particular
disease is present within the patient, the patient's prognosis, or
whether a particular treatment regimen is effective. For example,
if the patient is being treated with a particular chemotherapeutic
regimen, a decreased level of expression of an immunogenic target
in the patient's tissues (i.e., in peripheral blood) may indicate
the regimen is decreasing the cancer load in that host. Similarly,
if the level of expression is increasing, another therapeutic
modality may need to be utilized. In one embodiment, nucleic acid
probes corresponding to a nucleic acid encoding an immunogenic
target may be attached to a biochip, as is known in the art, for
the detection and quantification of expression in the host.
[0065] It is also possible to use nucleic acids, proteins,
derivatives therefrom, or antibodies thereto as reagents in drug
screening assays. The reagents may be used to ascertain the effect
of a drug candidate on the expression of the immunogenic target in
a cell line, or a cell or tissue of a patient. The expression
profiling technique may be combined with high throughput screening
techniques to allow rapid identification of useful compounds and
monitor the effectiveness of treatment with a drug candidate (see,
for example, Zlokarnik, et al., Science 279, 84-8 (1998)). Drug
candidates may be chemical compounds, nucleic acids, proteins,
antibodies, or derivatives therefrom, whether naturally occurring
or synthetically derived. Drug candidates thus identified may be
utilized, among other uses, as pharmaceutical compositions for
administration to patients or for use in further screening
assays.
[0066] Administration of a composition of the present invention to
a host may be accomplished using any of a variety of techniques
known to those of skill in the art. The composition(s) may be
processed in accordance with conventional methods of pharmacy to
produce medicinal agents for administration to patients, including
humans and other mammals (i.e., a "pharmaceutical composition").
The pharmaceutical composition is preferably made in the form of a
dosage unit containing a given amount of DNA, viral vector
particles, polypeptide or peptide, for example. A suitable daily
dose for a human or other mammal may vary widely depending on the
condition of the patient and other factors, but, once again, can be
determined using routine methods.
[0067] The pharmaceutical composition may be administered orally,
parentally, by inhalation spray, rectally, intranodally, or
topically in dosage unit formulations containing conventional
pharmaceutically acceptable carriers, adjuvants, and vehicles. The
term "pharmaceutically acceptable carrier" or "physiologically
acceptable carrier" as used herein refers to one or more
formulation materials suitable for accomplishing or enhancing the
delivery of a nucleic acid, polypeptide, or peptide as a
pharmaceutical composition. A "pharmaceutical composition" is a
composition comprising a therapeutically effective amount of a
nucleic acid or polypeptide. The terms "effective amount" and
"therapeutically effective amount" each refer to the amount of a
nucleic acid or polypeptide used to induce or enhance an effective
immune response. It is preferred that compositions of the present
invention provide for the induction or enhancement of an anti-tumor
immune response in a host which protects the host from the
development of a tumor and/or allows the host to eliminate an
existing tumor from the body.
[0068] For oral administration, the pharmaceutical composition may
be of any of several forms including, for example, a capsule, a
tablet, a suspension, or liquid, among others. Liquids may be
administered by injection as a composition wraith suitable carriers
including saline, dextrose, or water. The term parenteral as used
herein includes subcutaneous, intravenous, intramuscular,
intrasternal, infusion, or intraperitoneal administration.
Suppositories for rectal administration of the drug can be prepared
by mixing the drug with suitable non-irritating excipient such as
cocoa butter and polyethylene glycols that are solid at ordinary
temperatures but liquid at the rectal temperature.
[0069] The dosage regimen for immunizing a host or otherwise
treating a disorder or a disease with a composition of this
invention is based on a variety of factors, including the type of
disease, the age, weight, sex, medical condition of the patient,
the severity of the condition, the route of administration, and the
particular compound employed. For example, a poxviral vector may be
administered as a composition comprising 1.times.10.sup.6
infectious particles per dose. Thus, the dosage regimen may vary
widely, but can be determined routinely using standard methods.
[0070] A prime-boost regimen may also be utilized (see, for
example, WO 01/30382 A1) in which the targeted immunogen is
initially administered in a priming step in one form followed by a
boosting step in which the targeted immunogen is administered in
another form. The form of the targeted immunogen in the priming and
boosting steps are different. For instance, if the priming step
utilized a nucleic acid, the boost may be administered as a
peptide. Similarly, where a priming step utilized one type of
recombinant virus (i.e., ALVAC), the boost step may utilize another
type of virus (i.e., NYVAC). This prime-boost method of
administration has been shown to induce strong immunological
responses.
[0071] While the compositions of the invention can be administered
as the sole active pharmaceutical agent, they can also be used in
combination with one or more other compositions or agents (i.e.,
other immunogenic targets, co-stimulatory molecules, adjuvants).
When administered as a combination, the individual components can
be formulated as separate compositions administered at the same
time or different times, or the components can be combined as a
single composition.
[0072] Injectable preparations, such as sterile injectable aqueous
or oleaginous suspensions, may be formulated according to known
methods using suitable dispersing or wetting agents and suspending
agents. The injectable preparation may also be a sterile injectable
solution or suspension in a non-toxic parenterally acceptable
diluent or solvent. Suitable vehicles and solvents that may be
employed are water, Ringer's solution, and isotonic sodium chloride
solution, among others. For instance, a viral vector such as a
poxvirus may be prepared in 0.4% NaCl. In addition, sterile, fixed
oils are conventionally employed as a solvent or suspending medium.
For this purpose, any bland fixed oil may be employed, including
synthetic mono- or diglycerides. In addition, fatty acids such as
oleic acid find use in the preparation of injectables.
[0073] For topical administration, a suitable topical dose of a
composition may be administered one to four, and preferably two or
three times daily. The dose may also be administered with
intervening days during which no does is applied. Suitable
compositions may comprise from 0.001% to 10% w/w, for example, from
1% to 20/0 by weight of the formulation, although it may comprise
as much as 1004 w/w, but preferably not more than 50/0 w/w, and
more preferably from 0.1% to 1% of the formulation. Formulations
suitable for topical administration include liquid or semi-liquid
preparations suitable for penetration through the skin (e.g.,
liniments, lotions, ointments, creams, or pastes) and drops
suitable for administration to the eye, ear, or nose.
[0074] The pharmaceutical compositions may also be prepared in a
solid form (including granules, powders or suppositories). The
pharmaceutical compositions may be subjected to conventional
pharmaceutical operations such as sterilization and/or may contain
conventional adjuvants, such as preservatives, stabilizers, wetting
agents, emulsifiers, buffers etc. Solid dosage forms for oral
administration may include capsules, tablets, pills, powders, and
granules. In such solid dosage forms, the active compound may be
admixed with at least one inert diluent such as sucrose, lactose,
or starch. Such dosage forms may also comprise, as in normal
practice, additional substances other than inert diluents, e.g.,
lubricating agents such as magnesium stearate. In the case of
capsules, tablets, and pills, the dosage forms may also comprise
buffering agents. Tablets and pills can additionally be prepared
with enteric coatings. Liquid dosage forms for oral administration
may include pharmaceutically acceptable emulsions, solutions,
suspensions, syrups, and elixirs containing inert diluents commonly
used in the art, such as water. Such compositions may also comprise
adjuvants, such as wetting sweetening, flavoring, and perfuming
agents.
[0075] Pharmaceutical compositions comprising a nucleic acid or
polypeptide of the present invention may take any of several forms
and may be administered by any of several routes. In preferred
embodiments, the compositions are administered via a parenteral
route (intradermal, intramuscular or subcutaneous) to induce an
immune response in the host. Alternatively, the composition may be
administered directly into a lymph node (intranodal) or tumor mass
(i.e., intratumoral administration). For example, the dose could be
administered subcutaneously at days 0, 7, and 14. Suitable methods
for immunization using compositions comprising TAs are known in the
art, as shown for p53 (Hollstein et al., 1991), p21-ras (Almoguera
et al., 1988), HER-2 (Fendly et al., 1990), the
melanomoia-associated antigens (MAGE-1; MAGE-2) (van der Bruggen et
al., 1991), p97 (Hu et al., 1988), melanoma-associated antigen E
(WO 99/30737) and carcinoembryonic antigen (CEA) (Kantor et al.,
1993; Fishbein et al., 1992; Kaufman et al., 1991), among
others.
[0076] Preferred embodiments of administratable compositions
include, for example, nucleic acids or polypeptides in liquid
preparations such as suspensions, syrups, or elixirs. Preferred
injectable preparations include, for example, nucleic acids or
polypeptides suitable for parental, subcutaneous, intradermal,
intramuscular or intravenous administration such as sterile
suspensions or emulsions. For example, a recombinant poxvirus may
be in admixture with a suitable carrier, diluent, or excipient such
as sterile water, physiological saline, glucose or the like. The
composition may also be provided in lyophilized form for
reconstituting, for instance, in isotonic aqueous, saline buffer.
In addition, the compositions can be co-administered or
sequentially administered with other antineoplastic, anti-tumor or
anti-cancer agents and/or with agents which reduce or alleviate ill
effects of antineoplastic, anti-tumor or anti-cancer agents.
[0077] A kit comprising a composition of the present invention is
also provided. The kit can include a separate container containing
a suitable carrier, diluent or excipient. The kit can also include
an additional anti-cancer, anti-tumor or antineoplastic agent
and/or an agent that reduces or alleviates ill effects of
antineoplastic, anti-tumor or anti-cancer agents for co- or
sequential-administration. Additionally, the kit can include
instructions for mixing or combining ingredients and/or
administration.
[0078] A better understanding of the present invention and of its
many advantages will be had from the following examples, given by
way of illustration.
EXAMPLES
Example 1
BFA5 Breast Cancer Antigen
[0079] A. Identification of BFA5
[0080] Microarray profiling analysis indicated that BFA5 was
expressed at low to high levels in 41 out of 54 breast tumor biopsy
samples (76%) and at high levels in 31 out of 54 breast tumors
(57%), as compared to a panel of 52 normal, non-tumor tissues. In
situ hybridization (ISH) was performed using a series of BFA5 DNA
probes and confirmed the microarray with at least 61% of the tumors
showing fairly strong signals. Further bioinformatics assessment
confirmed the results of these gene expression analysis
results.
[0081] Sequence analysis of the BFA5 nucleotide sequence revealed a
high degree of similarity to two unidentified human genes: KIAA1074
(GenBank Accession No. XM.sub.--159732); and, KIAA0565 (GenBank
Accession No. AB011137) isolated from a number of fetal and adult
brain cDNA clones (Kikuno, et al. The complete sequences of 100 new
cDNA clones from brain which code for large proteins in vitro. DNA
Res. 6: 197-205). These genes were found to contain putative Zn
finger regions and a nuclear localization sequence. BFA5 was
suggested by others to be a potential breast cancer antigen (Jager,
et al. 2001. Identification of a tissue-specific putative
transcription factor in breast tissue by serological screening of a
breast cancer library. Cancer Res. 61: 2055-2061 and WO 01/47959).
In each of these publications, the nucleotide sequence BFA5 was
designated NYBR-1 ("New York Breast Cancer-1"; GenBank Accession
Nos. AF269087 (nucleotide) and AAK27325 (amino acid).
[0082] As shown previously by Jager, et al. and described in WO
01/47959, supra, BFA5 is specifically expressed in mammary gland,
being expressed in 12/19 breast tumors analyzed. The structure of
the BFA5/NYBR-1 gene has revealed that it encodes a 150-160 kD
nuclear transcription factor with a bZIP site (DNA-binding domain
followed by a leucine zipper motif). The gene also contains 5
tandem ankyrin repeats implying a role in protein-protein
interactions. These ankyrin repeats may play a role in
homo-dimerization of the protein. The BFA5 cDNA sequence is shown
in FIG. 4 and SEQ ID NO.: 5. The BFA5 amino acid sequence is shown
in FIG. 5 and SEQ ID NO.: 6.
[0083] B. Immunoreactivity of BFA5
[0084] 1. Activation of Human T Cells and IFN-.gamma. Secretion in
ELISPOT.
[0085] A library of 100 peptides from the BFA5/NYBR-1 coding
sequence that are predicted to be medium to high binders to
HLA-A*0201 were designed using Rammensee and Parker algorithms. The
library was sub-divided into 10 pools of ten peptides (Table III),
and each pool was used to activate 10 different T cell cultures
after pulsing peptides on to mature autologous dendritic cells. Two
experiments were performed with the library of BFA5/NYBR-1 peptides
demonstrating immunoreactivity in HLA-A*0201 human T cells, as
described below.
3TABLE III BFA5 Peptide Pools Peptide Group CLP number Sequence
BFA5 2983 LMDMQTFKA Group 1 2984 KVSIPTKAL 2985 SIPTKALEL 2986
LELKNEQTL 2987 TVSQKDVCL 2988 SVPNKALEL 2989 CETVSQKDV 2990
KINGKLEES 2991 SLVEKTPDE 2992 SLCETVSQK BFA5 2993 EIDKINGKL Group 2
2994 MLLQQNVDV 2995 NMWLQQQLV 2996 FLVDRKCQL 2997 YLLHENCML 2998
SLFESSAKI 2999 KITIDIHFL 3000 QLQSKNMWL 3001 SLDQKLFQL 3002
FLLIKNANA BFA5 3003 KILDTVHSC Group 3 3004 SLSKILDTV 3005 ILIDSGADI
3006 KVMEINREV 3007 KLLSHGAVI 3009 AVYSEILSV 3010 KMNVDVSST 3011
ILSVVAKLL 3012 VLIAENTML BFA5 3013 KLSKNHQNT Group 4 3014 SLTPLLLSI
3015 SQYSGQLKV 3016 KELEVKQQL 3017 QIMEYIRKL 3018 AMLKLEIAT 3019
VLHQPLSEA 3020 GLLKATCGM 3021 GLLKANCGM 3022 QQLEQALRI BFA5 3023
CMLKKEIAM Group 5 3024 EQMKKKFCV 3025 IQDIELKSV 3026 SVPNKAFEL 3027
SIYQKVMEI 3028 NLNYAGDAL 3029 AVQDHDQIV BFA5 3033 FESSAKIQV Group 6
3034 GVTAEHYAV 3035 RVTSNKTKV 3036 TVSQKDVCV 3037 KSQEPAFHI 3038
KVLIAENTM 3039 MLKLEIATL 3040 EILSVVAKL 3041 MLKKEIAML 3042
LLKEKNEEI BFA5 3043 ALRIQDIEL Group 7 3044 KIREELGRI 3045 TLKLKEESL
3046 ILNEKIREE 3047 VLKKKLSEA 3048 GTSDKIQCL 3049 GADINLVDV 3050
ELCSVRLTL 3051 SVESNLNQV 3052 SLKINLNYA BFA5 3053 KTPDEAASL Group 8
3054 ATCGMKVSI 3055 LSHGAVIEV 3056 EIAMLKLEI 3057 AELQMTLKL 3058
VFAADICGV 3060 PAIEMQNSV 3061 EIFNYNNHL 3062 ILKEKNAEL BFA5 3063
QLVHAHKKA Group 9 3065 NIQDAQKRT 3066 NLVDVYGNM 3067 KCTALMLAV 3068
KIQCLEKAT 3069 KIAWEKKET 3070 IAWEKKEDT 3071 VGMLLQQNV 3072
VKTGCVARV BFA5 3074 ALHYAVYSE Group 10 3075 QMKKKFCVL 3076
ALQCHQEAC 3077 SEQIVEFLL 3078 AVIEVHNKA 3079 AVTCGFHHI 3080
ACLQRKMNV 3081 SLVEGTSDK
[0086] ELISPOT analysis was performed on human T-cell cultures
activated through four rounds of stimulation with each pool of BFA5
peptides. Reactivity against a CMV pp65 peptide and a Flu matrix
peptide were used as positive controls for T-cell activation in the
experiments. Each experiment was performed with PBMC and dendritic
cells from a single HLA-A*0201.sup.+ donor designated as "AP10".
The results show that, although BFA4 is markedly reactive with high
ELISPOT counts per 100,000 cells in the assay, BFA5 is even more
reactive with 9/10 pools demonstrating ELISPOT reactivity. Similar
results were obtained for both BFA4 and BFA5/NYBR-1 with a
different HLA-A*0201. The bars reach a maximum at 600 spots because
beyond that the ELISPOT reader does not give accurate counts.
Cultures having a reading of 600 spots have more than this number
of spots.
[0087] A large number of the BFA5 peptide pools of are reactive as
shown by the high levels of IFN-.gamma. production. Each reactive
peptide pool was then separated into individual peptides and
analyzed for immunogenicity using ELISPOT analysis to isolate
single reactive BFA5 peptides. BFA5 is highly immunogenic with
several reactive single peptides than that of BFA4. Similar results
were obtained in two independent PBMC culture experiments.
[0088] In addition to ELISPOT analysis, human T cells activated by
BFA5 peptides were assayed to determine their ability to function
as CTL. The cells were activated using peptide-pulsed dendritic
cells followed by CD40 ligand-activated B cells (5 rounds of
stimulation). The experiment shown was performed with isolated PBMC
from HLA-A*0201.sup.+ donor AP31. Isolated T cells were tested in
.sup.51Cr-release assays usinig peptide-loaded T2 cells. The %
specific lysis at a 10:1, 5:1, and 1:1 T-cell to target ratio is
shown for T2 cells pulsed with either pools of BFA5/NYBR-1 peptides
or with individual peptides. The graph shows CTL activity induced
against targets loaded with a c non-specific HLA-A*0201-binding HIV
peptide (control) followed by the CTL activity against the peptide
pool (Pool 1 etc.) and then the activity induced by individual
peptides from the respective pool to the right. A high level of
cytotoxicity was observed for some peptides at a 1:1 E:T ratio. CTL
activity (percent specific lysis) induced by the control HIV
peptide was generally <10%. Similar results were obtained with
another PBMC donor expressing HLA-A*0201 (AP10). A large number of
BFA5 peptides trigger T cell-mediated cytotoxicity of BFA5
peptide-loaded target cells. Table IV lists those peptides having
immunogenic properties. Five peptides (LMDMQTFKA, ILIDSGADI,
ILSVVAKLL, SQYSGQLKV, and ELCSJRLTL) were found to induce both
IFN-.gamma. secretion and CTL activity in T cells from both
donors.
4TABLE IV Immunoreactive peptides from BFA5 BFA5 peptides BFA5
peptides eliciting high IFN-.gamma. inducing CTL release (>200
spots/ lysis of 100,000 cells) pulsed cells Donor AP10 Donor AP31
Donor AP10 Donor AP31 LMDMQTFKA LMDMQTFKA LMDMQTFKA LMDMQTFKA
KVSIPTKAL KVSIPTKAL SIPTKALEL SIPTKALEL TVSQKDVCL SVPNKALEL
YLLHENCML YLLHENCML YLLHENCML QLQSKNMWL QLQSKNMWL QLQSKNMWL
SLSKILDTV SLSKILDTV SLSKILDTV ILIDSGADI ILIDSGADI ILIDSGADI
ILIDSGADI KVMEINREV AVYSEILSV ILSVVAKLL ILSVVAKLL ILSVVAKLL
ILSVVAKLL SLTPLLLSI SLTPLLLSI SLTPLLLSI SQYSGQLKV SQYSGQLKV
SQYSGQLKV SQYSGQLKV QIMEYIRKL QIMEYIRKL QIMEYIRKL SVPNKAFEL
NLNYAGDAL NLNYAGDAL GVTAEHYAV KSQEPAFHI MLKLEIATL MLKLEIATL
MLKLEIATL MLKKEIAML ALRIQDIEL VLKKKLSEA ELCSVRLTL ELCSVRLTL
ELCSVRLTL ELCSVRLTL SLKINLNYA SLKINLNYA SLKINLNYA ATCGMKVSI
ATCGMKVSI AELQMTLKL AELQMTLKL AELQMTLKL VFAADICGV ILKEKNAEL
ILKEKNAEL NLVDVYGNM NLVDVYGNM KCTALMLAV
[0089] C. Immunological Reagents
[0090] Polyclonal antisera were generated against the following
series of 22- to 23-mer peptides of BFA5:
5 BFA5 KLH-MTKRKKTINLNIQDAQKRTALHW (CLP-2977) (1-23) BFA5
KLH-TSEKFTWPAKGRPRKIAWEKKED (CLP-2978) (312-334) BFA5
KLH-DEILPSESKQKDYEENSWDTESL (CLP-2979) (612-634) BFA5
KLH-RLTLNQEEEKRRNADILNEKIRE (CLP-2980) (972-994) BFA5
KLH-AENTMLTSKLKEKQDKEILEAEI (CLP-2981) (1117-1139) BFA5
KLH-NYNNHLKNRIYQYEKEKAETENS (CLP-2982) (1319-1341)
[0091] Prebleed samples from rabbits were processed and stored at
-20.degree. C. Rabbits were immunized as follows: 1) the peptides
were administered as an emulsion with Freund's Complete Adjuvant
(FCA); and, 2) two weeks later, the peptides were coupled with
Keyhole-Limpet Hemocyanin (KLH)-coupled and administered as an
emulsion with Freund's Incomplete Adjuvant FIA. The following
results were observed:
6 TABLE V IgG titer .times. 10.sup.5 (after IgG titer .times.
10.sup.5 (after second first Immunization Immunization
Peptide/protein Rb1/Rb2) Rb1/Rb2) CLP 2977 25/6 256/64 CLP 2978
25/25 64/256 CLP 2979 12/25 256/512 CLP 2980 25/12 1024/128 CLP
2981 8/4 256/64 CLP 2982 2/2 64/32
[0092] Prebleed sample results exhibited IgG titers <100 for all
samples.
[0093] To assess the quality of the polyclonal antisera, western
blots were performed using sera against BFA5. Sera were separately
screened against cell extracts obtained from the BT474, MDMB453,
MCF-7, Calu-6, and CosA2 cells. The approximate expected MW.sub.r
of BFA5 protein is 153 kDa. A 220 kD band was observed in the BT474
extract with CLP2980 antibody but not in the MDMB453 cell extracts
however a .about.130 kD band was present in the MDMB453 extract.
Both bands were found to be consistent with the polyclonal
antibosera tested in this analysis. Neither of these bands is
present in the negative control. Thus, it can be concluded that the
polyclonal antisera are specific for BFA5.
[0094] While the present invention has been described in terms of
the preferred embodiments, it is understood that variations and
modifications will occur to those skilled in the art. Therefore, it
is intended that the appended claims cover all such equivalent
variations that come within the scope of the invention as claimed.
Sequence CWU 1
1
106 1 3846 DNA Homo sapiens 1 atggtccgga aaaagaaccc ccctctgaga
aacgttgcaa gtgaaggcga gggccagatc 60 ctggagccta taggtacaga
aagcaaggta tctggaaaga acaaagaatt ctctgcagat 120 cagatgtcag
aaaatacgga tcagagtgat gctgcagaac taaatcataa ggaggaacat 180
agcttgcatg ttcaagatcc atcttctagc agtaagaagg acttgaaaag cgcagttctg
240 agtgagaagg ctggcttcaa ttatgaaagc cccagtaagg gaggaaactt
tccctccttt 300 ccgcatgatg aggtgacaga cagaaatatg ttggctttct
catttccagc tgctggggga 360 gtctgtgagc ccttgaagtc tccgcaaaga
gcagaggcag atgaccctca agatatggcc 420 tgcaccccct caggggactc
actggagaca aaggaagatc agaagatgtc accaaaggct 480 acagaggaaa
cagggcaagc acagagtggt caagccaatt gtcaaggttt gagcccagtt 540
tcagtggcct caaaaaaccc acaagtgcct tcagatgggg gtgtaagact gaataaatcc
600 aaaactgact tactggtgaa tgacaaccca gacccggcac ctctgtctcc
agagcttcag 660 gactttaaat gcaatatctg tggatatggt tactacggca
acgaccccac agatctgatt 720 aagcacttcc gaaagtatca cttaggactg
cataaccgca ccaggcaaga tgctgagctg 780 gacagcaaaa tcttggccct
tcataacatg gtgcagttca gccattccaa agacttccag 840 aaggtcaacc
gttctgtgtt ttctggtgtg ctgcaggaca tcaattcttc aaggcctgtt 900
ttactaaatg ggacctatga tgtgcaggtg acttcaggtg gaacattcat tggcattgga
960 cggaaaacac cagattgcca agggaacacc aagtatttcc gctgtaaatt
ctgcaatttc 1020 acttatatgg gcaactcatc caccgaatta gaacaacatt
ttcttcagac tcacccaaac 1080 aaaataaaag cttctctccc ctcctctgag
gttgcaaaac cttcagagaa aaactctaac 1140 aagtccatcc ctgcacttca
atccagtgat tctggagact tgggaaaatg gcaggacaag 1200 ataacagtca
aagcaggaga tgacactcct gttgggtact cagtgcccat aaagcccctc 1260
gattcctcta gacaaaatgg tacagaggcc accagttact actggtgtaa attttgtagt
1320 ttcagctgtg agtcatctag ctcacttaaa ctgctagaac attatggcaa
gcagcacgga 1380 gcagtgcagt caggcggcct taatccagag ttaaatgata
agctttccag gggctctgtc 1440 attaatcaga atgatctagc caaaagttca
gaaggagaga caatgaccaa gacagacaag 1500 agctcgagtg gggctaaaaa
gaaggacttc tccagcaagg gagccgagga taatatggta 1560 acgagctata
attgtcagtt ctgtgacttc cgatattcca aaagccatgg ccctgatgta 1620
attgtagtgg ggccacttct ccgtcattat caacagctcc ataacattca caagtgtacc
1680 attaaacact gtccattctg tcccagagga ctttgcagcc cagaaaagca
ccttggagaa 1740 attacttatc cgtttgcttg tagaaaaagt aattgttccc
actgtgcact cttgcttctg 1800 cacttgtctc ctggggcggc tggaagctcg
cgagtcaaac atcagtgcca tcagtgttca 1860 ttcaccaccc ctgacgtaga
tgtactcctc tttcactatg aaagtgtgca tgagtcccaa 1920 gcatcggatg
tcaaacaaga agcaaatcac ctgcaaggat cggatgggca gcagtctgtc 1980
aaggaaagca aagaacactc atgtaccaaa tgtgatttta ttacccaagt ggaagaagag
2040 atttcccgac actacaggag agcacacagc tgctacaaat gccgtcagtg
cagttttaca 2100 gctgccgata ctcagtcact actggagcac ttcaacactg
ttcactgcca ggaacaggac 2160 atcactacag ccaacggcga agaggacggt
catgccatat ccaccatcaa agaggagccc 2220 aaaattgact tcagggtcta
caatctgcta actccagact ctaaaatggg agagccagtt 2280 tctgagagtg
tggtgaagag agagaagctg gaagagaagg acgggctcaa agagaaagtt 2340
tggaccgaga gttccagtga tgaccttcgc aatgtgactt ggagaggggc agacatcctg
2400 cgggggagtc cgtcatacac ccaagcaagc ctggggctgc tgacgcctgt
gtctggcacc 2460 caagagcaga caaagactct aagggatagt cccaatgtgg
aggccgccca tctggcgcga 2520 cctatttatg gcttggctgt ggaaaccaag
ggattcctgc agggggcgcc agctggcgga 2580 gagaagtctg gggccctccc
ccagcagtat cctgcatcgg gagaaaacaa gtccaaggat 2640 gaatcccagt
ccctgttacg gaggcgtaga ggctccggtg ttttttgtgc caattgcctg 2700
accacaaaga cctctctctg gcgaaagaat gcaaatggcg gatatgtatg caacgcgtgt
2760 ggcctctacc agaagcttca ctcgactccc aggcctttaa acatcattaa
acaaaacaac 2820 ggtgagcaga ttattaggag gagaacaaga aagcgcctta
acccagaggc acttcaggct 2880 gagcagctca acaaacagca gaggggcagc
aatgaggagc aagtcaatgg aagcccgtta 2940 gagaggaggt cagaagatca
tctaactgaa agtcaccaga gagaaattcc actccccagc 3000 ctaagtaaat
acgaagccca gggttcattg actaaaagcc attctgctca gcagccagtc 3060
ctggtcagcc aaactctgga tattcacaaa aggatgcaac ctttgcacat tcagataaaa
3120 agtcctcagg aaagtactgg agatccagga aatagttcat ccgtatctga
agggaaagga 3180 agttctgaga gaggcagtcc tatagaaaag tacatgagac
ctgcgaaaca cccaaattat 3240 tcaccaccag gcagccctat tgaaaagtac
cagtacccac tttttggact tccctttgta 3300 cataatgact tccagagtga
agctgattgg ctgcggttct ggagtaaata taagctctcc 3360 gttcctggga
atccgcacta cttgagtcac gtgcctggcc taccaaatcc ttgccaaaac 3420
tatgtgcctt atcccacctt caatctgcct cctcattttt cagctgttgg atcagacaat
3480 gacattcctc tagatttggc gatcaagcat tccagacctg ggccaactgc
aaacggtgcc 3540 tccaaggaga aaacgaaggc accaccaaat gtaaaaaatg
aaggtccctt gaatgtagta 3600 aaaacagaga aagttgatag aagtactcaa
gatgaacttt caacaaaatg tgtgcactgt 3660 ggcattgtct ttctggatga
agtgatgtat gctttgcata tgagttgcca tggtgacagt 3720 ggacctttcc
agtgcagcat atgccagcat ctttgcacgg acaaatatga cttcacaaca 3780
catatccaga ggggcctgca taggaacaat gcacaagtgg aaaaaaatgg aaaacctaaa
3840 gagtaa 3846 2 1281 PRT Homo sapiens 2 Met Val Arg Lys Lys Asn
Pro Pro Leu Arg Asn Val Ala Ser Glu Gly 1 5 10 15 Glu Gly Gln Ile
Leu Glu Pro Ile Gly Thr Glu Ser Lys Val Ser Gly 20 25 30 Lys Asn
Lys Glu Phe Ser Ala Asp Gln Met Ser Glu Asn Thr Asp Gln 35 40 45
Ser Asp Ala Ala Glu Leu Asn His Lys Glu Glu His Ser Leu His Val 50
55 60 Gln Asp Pro Ser Ser Ser Ser Lys Lys Asp Leu Lys Ser Ala Val
Leu 65 70 75 80 Ser Glu Lys Ala Gly Phe Asn Tyr Glu Ser Pro Ser Lys
Gly Gly Asn 85 90 95 Phe Pro Ser Phe Pro His Asp Glu Val Thr Asp
Arg Asn Met Leu Ala 100 105 110 Phe Ser Phe Pro Ala Ala Gly Gly Val
Cys Glu Pro Leu Lys Ser Pro 115 120 125 Gln Arg Ala Glu Ala Asp Asp
Pro Gln Asp Met Ala Cys Thr Pro Ser 130 135 140 Gly Asp Ser Leu Glu
Thr Lys Glu Asp Gln Lys Met Ser Pro Lys Ala 145 150 155 160 Thr Glu
Glu Thr Gly Gln Ala Gln Ser Gly Gln Ala Asn Cys Gln Gly 165 170 175
Leu Ser Pro Val Ser Val Ala Ser Lys Asn Pro Gln Val Pro Ser Asp 180
185 190 Gly Gly Val Arg Leu Asn Lys Ser Lys Thr Asp Leu Leu Val Asn
Asp 195 200 205 Asn Pro Asp Pro Ala Pro Leu Ser Pro Glu Leu Gln Asp
Phe Lys Cys 210 215 220 Asn Ile Cys Gly Tyr Gly Tyr Tyr Gly Asn Asp
Pro Thr Asp Leu Ile 225 230 235 240 Lys His Phe Arg Lys Tyr His Leu
Gly Leu His Asn Arg Thr Arg Gln 245 250 255 Asp Ala Glu Leu Asp Ser
Lys Ile Leu Ala Leu His Asn Met Val Gln 260 265 270 Phe Ser His Ser
Lys Asp Phe Gln Lys Val Asn Arg Ser Val Phe Ser 275 280 285 Gly Val
Leu Gln Asp Ile Asn Ser Ser Arg Pro Val Leu Leu Asn Gly 290 295 300
Thr Tyr Asp Val Gln Val Thr Ser Gly Gly Thr Phe Ile Gly Ile Gly 305
310 315 320 Arg Lys Thr Pro Asp Cys Gln Gly Asn Thr Lys Tyr Phe Arg
Cys Lys 325 330 335 Phe Cys Asn Phe Thr Tyr Met Gly Asn Ser Ser Thr
Glu Leu Glu Gln 340 345 350 His Phe Leu Gln Thr His Pro Asn Lys Ile
Lys Ala Ser Leu Pro Ser 355 360 365 Ser Glu Val Ala Lys Pro Ser Glu
Lys Asn Ser Asn Lys Ser Ile Pro 370 375 380 Ala Leu Gln Ser Ser Asp
Ser Gly Asp Leu Gly Lys Trp Gln Asp Lys 385 390 395 400 Ile Thr Val
Lys Ala Gly Asp Asp Thr Pro Val Gly Tyr Ser Val Pro 405 410 415 Ile
Lys Pro Leu Asp Ser Ser Arg Gln Asn Gly Thr Glu Ala Thr Ser 420 425
430 Tyr Tyr Trp Cys Lys Phe Cys Ser Phe Ser Cys Glu Ser Ser Ser Ser
435 440 445 Leu Lys Leu Leu Glu His Tyr Gly Lys Gln His Gly Ala Val
Gln Ser 450 455 460 Gly Gly Leu Asn Pro Glu Leu Asn Asp Lys Leu Ser
Arg Gly Ser Val 465 470 475 480 Ile Asn Gln Asn Asp Leu Ala Lys Ser
Ser Glu Gly Glu Thr Met Thr 485 490 495 Lys Thr Asp Lys Ser Ser Ser
Gly Ala Lys Lys Lys Asp Phe Ser Ser 500 505 510 Lys Gly Ala Glu Asp
Asn Met Val Thr Ser Tyr Asn Cys Gln Phe Cys 515 520 525 Asp Phe Arg
Tyr Ser Lys Ser His Gly Pro Asp Val Ile Val Val Gly 530 535 540 Pro
Leu Leu Arg His Tyr Gln Gln Leu His Asn Ile His Lys Cys Thr 545 550
555 560 Ile Lys His Cys Pro Phe Cys Pro Arg Gly Leu Cys Ser Pro Glu
Lys 565 570 575 His Leu Gly Glu Ile Thr Tyr Pro Phe Ala Cys Arg Lys
Ser Asn Cys 580 585 590 Ser His Cys Ala Leu Leu Leu Leu His Leu Ser
Pro Gly Ala Ala Gly 595 600 605 Ser Ser Arg Val Lys His Gln Cys His
Gln Cys Ser Phe Thr Thr Pro 610 615 620 Asp Val Asp Val Leu Leu Phe
His Tyr Glu Ser Val His Glu Ser Gln 625 630 635 640 Ala Ser Asp Val
Lys Gln Glu Ala Asn His Leu Gln Gly Ser Asp Gly 645 650 655 Gln Gln
Ser Val Lys Glu Ser Lys Glu His Ser Cys Thr Lys Cys Asp 660 665 670
Phe Ile Thr Gln Val Glu Glu Glu Ile Ser Arg His Tyr Arg Arg Ala 675
680 685 His Ser Cys Tyr Lys Cys Arg Gln Cys Ser Phe Thr Ala Ala Asp
Thr 690 695 700 Gln Ser Leu Leu Glu His Phe Asn Thr Val His Cys Gln
Glu Gln Asp 705 710 715 720 Ile Thr Thr Ala Asn Gly Glu Glu Asp Gly
His Ala Ile Ser Thr Ile 725 730 735 Lys Glu Glu Pro Lys Ile Asp Phe
Arg Val Tyr Asn Leu Leu Thr Pro 740 745 750 Asp Ser Lys Met Gly Glu
Pro Val Ser Glu Ser Val Val Lys Arg Glu 755 760 765 Lys Leu Glu Glu
Lys Asp Gly Leu Lys Glu Lys Val Trp Thr Glu Ser 770 775 780 Ser Ser
Asp Asp Leu Arg Asn Val Thr Trp Arg Gly Ala Asp Ile Leu 785 790 795
800 Arg Gly Ser Pro Ser Tyr Thr Gln Ala Ser Leu Gly Leu Leu Thr Pro
805 810 815 Val Ser Gly Thr Gln Glu Gln Thr Lys Thr Leu Arg Asp Ser
Pro Asn 820 825 830 Val Glu Ala Ala His Leu Ala Arg Pro Ile Tyr Gly
Leu Ala Val Glu 835 840 845 Thr Lys Gly Phe Leu Gln Gly Ala Pro Ala
Gly Gly Glu Lys Ser Gly 850 855 860 Ala Leu Pro Gln Gln Tyr Pro Ala
Ser Gly Glu Asn Lys Ser Lys Asp 865 870 875 880 Glu Ser Gln Ser Leu
Leu Arg Arg Arg Arg Gly Ser Gly Val Phe Cys 885 890 895 Ala Asn Cys
Leu Thr Thr Lys Thr Ser Leu Trp Arg Lys Asn Ala Asn 900 905 910 Gly
Gly Tyr Val Cys Asn Ala Cys Gly Leu Tyr Gln Lys Leu His Ser 915 920
925 Thr Pro Arg Pro Leu Asn Ile Ile Lys Gln Asn Asn Gly Glu Gln Ile
930 935 940 Ile Arg Arg Arg Thr Arg Lys Arg Leu Asn Pro Glu Ala Leu
Gln Ala 945 950 955 960 Glu Gln Leu Asn Lys Gln Gln Arg Gly Ser Asn
Glu Glu Gln Val Asn 965 970 975 Gly Ser Pro Leu Glu Arg Arg Ser Glu
Asp His Leu Thr Glu Ser His 980 985 990 Gln Arg Glu Ile Pro Leu Pro
Ser Leu Ser Lys Tyr Glu Ala Gln Gly 995 1000 1005 Ser Leu Thr Lys
Ser His Ser Ala Gln Gln Pro Val Leu Val Ser 1010 1015 1020 Gln Thr
Leu Asp Ile His Lys Arg Met Gln Pro Leu His Ile Gln 1025 1030 1035
Ile Lys Ser Pro Gln Glu Ser Thr Gly Asp Pro Gly Asn Ser Ser 1040
1045 1050 Ser Val Ser Glu Gly Lys Gly Ser Ser Glu Arg Gly Ser Pro
Ile 1055 1060 1065 Glu Lys Tyr Met Arg Pro Ala Lys His Pro Asn Tyr
Ser Pro Pro 1070 1075 1080 Gly Ser Pro Ile Glu Lys Tyr Gln Tyr Pro
Leu Phe Gly Leu Pro 1085 1090 1095 Phe Val His Asn Asp Phe Gln Ser
Glu Ala Asp Trp Leu Arg Phe 1100 1105 1110 Trp Ser Lys Tyr Lys Leu
Ser Val Pro Gly Asn Pro His Tyr Leu 1115 1120 1125 Ser His Val Pro
Gly Leu Pro Asn Pro Cys Gln Asn Tyr Val Pro 1130 1135 1140 Tyr Pro
Thr Phe Asn Leu Pro Pro His Phe Ser Ala Val Gly Ser 1145 1150 1155
Asp Asn Asp Ile Pro Leu Asp Leu Ala Ile Lys His Ser Arg Pro 1160
1165 1170 Gly Pro Thr Ala Asn Gly Ala Ser Lys Glu Lys Thr Lys Ala
Pro 1175 1180 1185 Pro Asn Val Lys Asn Glu Gly Pro Leu Asn Val Val
Lys Thr Glu 1190 1195 1200 Lys Val Asp Arg Ser Thr Gln Asp Glu Leu
Ser Thr Lys Cys Val 1205 1210 1215 His Cys Gly Ile Val Phe Leu Asp
Glu Val Met Tyr Ala Leu His 1220 1225 1230 Met Ser Cys His Gly Asp
Ser Gly Pro Phe Gln Cys Ser Ile Cys 1235 1240 1245 Gln His Leu Cys
Thr Asp Lys Tyr Asp Phe Thr Thr His Ile Gln 1250 1255 1260 Arg Gly
Leu His Arg Asn Asn Ala Gln Val Glu Lys Asn Gly Lys 1265 1270 1275
Pro Lys Glu 1280 3 1203 DNA Homo sapiens 3 atggccgagc tgcgcctgaa
gggcagcagc aacaccacgg agtgtgttcc cgtgcccacc 60 tccgagcacg
tggccgagat cgtgggcagg caaggctgca agattaaggc cttgagggcc 120
aagaccaaca cctacatcaa gacaccggtg aggggcgagg aaccagtgtt catggtgaca
180 gggcgacggg aggacgtggc cacagcccgg cgggaaatca tctcagcagc
ggagcacttc 240 tccatgatcc gtgcctcccg caacaagtca ggcgccgcct
ttggtgtggc tcctgctctg 300 cccggccagg tgaccatccg tgtgcgggtg
ccctaccgcg tggtggggct ggtggtgggc 360 cccaaagggg caaccatcaa
gcgcatccag cagcaaacca acacatacat tatcacacca 420 agccgtgacc
gcgaccccgt gttcgagatc acgggtgccc caggcaacgt ggagcgtgcg 480
cgcgaggaga tcgagacgca catcgcggtg cgcactggca agatcctcga gtacaacaat
540 gaaaacgact tcctggcggg gagccccgac gcagcaatcg atagccgcta
ctccgacgcc 600 tggcgggtgc accagcccgg ctgcaagccc ctctccacct
tccggcagaa cagcctgggc 660 tgcatcggcg agtgcggagt ggactctggc
tttgaggccc cacgcctggg tgagcagggc 720 ggggactttg gctacggcgg
gtacctcttt ccgggctatg gcgtgggcaa gcaggatgtg 780 tactacggcg
tggccgagac tagccccccg ctgtgggcgg gccaggagaa cgccacgccc 840
acctccgtgc tcttctcctc tgcctcctcc tcctcctcct cttccgccaa ggcccgcgct
900 gggcccccgg gcgcacaccg ctcccctgcc acttccgcgg gacccgagct
ggccggactc 960 ccgaggcgcc ccccgggaga gccgctccag ggcttctcta
aacttggtgg gggcggcctg 1020 cggagccccg gcggcgggcg ggattgcatg
gtctgctttg agagcgaagt gactgccgcc 1080 cttgtgccct gcggacacaa
cctgttctgc atggagtgtg cagtacgcat ctgcgagagg 1140 acggacccag
agtgtcccgt ctgccacatc acagccgcgc aagccatccg aatattctcc 1200 taa
1203 4 400 PRT Homo sapiens 4 Met Ala Glu Leu Arg Leu Lys Gly Ser
Ser Asn Thr Thr Glu Cys Val 1 5 10 15 Pro Val Pro Thr Ser Glu His
Val Ala Glu Ile Val Gly Arg Gln Gly 20 25 30 Cys Lys Ile Lys Ala
Leu Arg Ala Lys Thr Asn Thr Tyr Ile Lys Thr 35 40 45 Pro Val Arg
Gly Glu Glu Pro Val Phe Met Val Thr Gly Arg Arg Glu 50 55 60 Asp
Val Ala Thr Ala Arg Arg Glu Ile Ile Ser Ala Ala Glu His Phe 65 70
75 80 Ser Met Ile Arg Ala Ser Arg Asn Lys Ser Gly Ala Ala Phe Gly
Val 85 90 95 Ala Pro Ala Leu Pro Gly Gln Val Thr Ile Arg Val Arg
Val Pro Tyr 100 105 110 Arg Val Val Gly Leu Val Val Gly Pro Lys Gly
Ala Thr Ile Lys Arg 115 120 125 Ile Gln Gln Gln Thr Asn Thr Tyr Ile
Ile Thr Pro Ser Arg Asp Arg 130 135 140 Asp Pro Val Phe Glu Ile Thr
Gly Ala Pro Gly Asn Val Glu Arg Ala 145 150 155 160 Arg Glu Glu Ile
Glu Thr His Ile Ala Val Arg Thr Gly Lys Ile Leu 165 170 175 Glu Tyr
Asn Asn Glu Asn Asp Phe Leu Ala Gly Ser Pro Asp Ala Ala 180 185 190
Ile Asp Ser Arg Tyr Ser Asp Ala Trp Arg Val His Gln Pro Gly Cys 195
200 205 Lys Pro Leu Ser Thr Phe Arg Gln Asn Ser Leu Gly Cys Ile Gly
Glu 210 215 220 Cys Gly Val Asp Ser Gly Phe Glu Ala Pro Arg Leu Gly
Glu Gln Gly 225 230 235 240 Gly Asp Phe Gly Tyr Gly Gly Tyr Leu Phe
Pro Gly Tyr Gly Val Gly 245 250 255 Lys Gln Asp Val Tyr Tyr Gly Val
Ala Glu Thr Ser Pro Pro Leu Trp 260 265 270 Ala Gly Gln Glu Asn Ala
Thr Pro Thr Ser Val Leu Phe Ser Ser Ala 275 280 285 Ser Ser Ser Ser
Ser Ser Ser Ala Lys Ala Arg Ala Gly Pro Pro Gly 290 295 300 Ala His
Arg Ser Pro Ala Thr Ser Ala
Gly Pro Glu Leu Ala Gly Leu 305 310 315 320 Pro Arg Arg Pro Pro Gly
Glu Pro Leu Gln Gly Phe Ser Lys Leu Gly 325 330 335 Gly Gly Gly Leu
Arg Ser Pro Gly Gly Gly Arg Asp Cys Met Val Cys 340 345 350 Phe Glu
Ser Glu Val Thr Ala Ala Leu Val Pro Cys Gly His Asn Leu 355 360 365
Phe Cys Met Glu Cys Ala Val Arg Ile Cys Glu Arg Thr Asp Pro Glu 370
375 380 Cys Pro Val Cys His Ile Thr Ala Ala Gln Ala Ile Arg Ile Phe
Ser 385 390 395 400 5 4026 DNA Homo sapiens 5 atgacaaaga ggaagaagac
catcaacctt aatatacaag acgcccagaa gaggactgct 60 ctacactggg
cctgtgtcaa tggccatgag gaagtagtaa catttctggt agacagaaag 120
tgccagcttg acgtccttga tggcgaacac aggacacctc tgatgaaggc tctacaatgc
180 catcaggagg cttgtgcaaa tattctgata gattctggtg ccgatataaa
tctcgtagat 240 gtgtatggca acatggctct ccattatgct gtttatagtg
agattttgtc agtggtggca 300 aaactgctgt cccatggtgc agtcatcgaa
gtgcacaaca aggctagcct cacaccactt 360 ttactatcca taacgaaaag
aagtgagcaa attgtggaat ttttgctgat aaaaaatgca 420 aatgcgaatg
cagttaataa gtataaatgc acagccctca tgcttgctgt atgtcatgga 480
tcatcagaga tagttggcat gcttcttcag caaaatgttg acgtctttgc tgcagatata
540 tgtggagtaa ctgcagaaca ttatgctgtt acttgtggat ttcatcacat
tcatgaacaa 600 attatggaat atatacgaaa attatctaaa aatcatcaaa
ataccaatcc agaaggaaca 660 tctgcaggaa cacctgatga ggctgcaccc
ttggcggaaa gaacacctga cacagctgaa 720 agcttggtgg aaaaaacacc
tgatgaggct gcacccttgg tggaaagaac acctgacacg 780 gctgaaagct
tggtggaaaa aacacctgat gaggctgcat ccttggtgga gggaacatct 840
gacaaaattc aatgtttgga gaaagcgaca tctggaaagt tcgaacagtc agcagaagaa
900 acacctaggg aaattacgag tcctgcaaaa gaaacatctg agaaatttac
gtggccagca 960 aaaggaagac ctaggaagat cgcatgggag aaaaaagaag
acacacctag ggaaattatg 1020 agtcccgcaa aagaaacatc tgagaaattt
acgtgggcag caaaaggaag acctaggaag 1080 atcgcatggg agaaaaaaga
aacacctgta aagactggat gcgtggcaag agtaacatct 1140 aataaaacta
aagttttgga aaaaggaaga tctaagatga ttgcatgtcc tacaaaagaa 1200
tcatctacaa aagcaagtgc caatgatcag aggttcccat cagaatccaa acaagaggaa
1260 gatgaagaat attcttgtga ttctcggagt ctctttgaga gttctgcaaa
gattcaagtg 1320 tgtatacctg agtctatata tcaaaaagta atggagataa
atagagaagt agaagagcct 1380 cctaagaagc catctgcctt caagcctgcc
attgaaatgc aaaactctgt tccaaataaa 1440 gcctttgaat tgaagaatga
acaaacattg agagcagatc cgatgttccc accagaatcc 1500 aaacaaaagg
actatgaaga aaattcttgg gattctgaga gtctctgtga gactgtttca 1560
cagaaggatg tgtgtttacc caaggctaca catcaaaaag aaatagataa aataaatgga
1620 aaattagaag agtctcctaa taaagatggt cttctgaagg ctacctgcgg
aatgaaagtt 1680 tctattccaa ctaaagcctt agaattgaag gacatgcaaa
ctttcaaagc ggagcctccg 1740 gggaagccat ctgccttcga gcctgccact
gaaatgcaaa agtctgtccc aaataaagcc 1800 ttggaattga aaaatgaaca
aacatggaga gcagatgaga tactcccatc agaatccaaa 1860 caaaaggact
atgaagaaaa ttcttgggat actgagagtc tctgtgagac tgtttcacag 1920
aaggatgtgt gtttacccaa ggctgcgcat caaaaagaaa tagataaaat aaatggaaaa
1980 ttagaagggt ctcctgttaa agatggtctt ctgaaggcta actgcggaat
gaaagtttct 2040 attccaacta aagccttaga attgatggac atgcaaactt
tcaaagcaga gcctcccgag 2100 aagccatctg ccttcgagcc tgccattgaa
atgcaaaagt ctgttccaaa taaagccttg 2160 gaattgaaga atgaacaaac
attgagagca gatgagatac tcccatcaga atccaaacaa 2220 aaggactatg
aagaaagttc ttgggattct gagagtctct gtgagactgt ttcacagaag 2280
gatgtgtgtt tacccaaggc tacacatcaa aaagaaatag ataaaataaa tggaaaatta
2340 gaagagtctc ctgataatga tggttttctg aaggctccct gcagaatgaa
agtttctatt 2400 ccaactaaag ccttagaatt gatggacatg caaactttca
aagcagagcc tcccgagaag 2460 ccatctgcct tcgagcctgc cattgaaatg
caaaagtctg ttccaaataa agccttggaa 2520 ttgaagaatg aacaaacatt
gagagcagat cagatgttcc cttcagaatc aaaacaaaag 2580 aaggttgaag
aaaattcttg ggattctgag agtctccgtg agactgtttc acagaaggat 2640
gtgtgtgtac ccaaggctac acatcaaaaa gaaatggata aaataagtgg aaaattagaa
2700 gattcaacta gcctatcaaa aatcttggat acagttcatt cttgtgaaag
agcaagggaa 2760 cttcaaaaag atcactgtga acaacgtaca ggaaaaatgg
aacaaatgaa aaagaagttt 2820 tgtgtactga aaaagaaact gtcagaagca
aaagaaataa aatcacagtt agagaaccaa 2880 aaagttaaat gggaacaaga
gctctgcagt gtgagattga ctttaaacca agaagaagag 2940 aagagaagaa
atgccgatat attaaatgaa aaaattaggg aagaattagg aagaatcgaa 3000
gagcagcata ggaaagagtt agaagtgaaa caacaacttg aacaggctct cagaatacaa
3060 gatatagaat tgaagagtgt agaaagtaat ttgaatcagg tttctcacac
tcatgaaaat 3120 gaaaattatc tcttacatga aaattgcatg ttgaaaaagg
aaattgccat gctaaaactg 3180 gaaatagcca cactgaaaca ccaataccag
gaaaaggaaa ataaatactt tgaggacatt 3240 aagattttaa aagaaaagaa
tgctgaactt cagatgaccc taaaactgaa agaggaatca 3300 ttaactaaaa
gggcatctca atatagtggg cagcttaaag ttctgatagc tgagaacaca 3360
atgctcactt ctaaattgaa ggaaaaacaa gacaaagaaa tactagaggc agaaattgaa
3420 tcacaccatc ctagactggc ttctgctgta caagaccatg atcaaattgt
gacatcaaga 3480 aaaagtcaag aacctgcttt ccacattgca ggagatgctt
gtttgcaaag aaaaatgaat 3540 gttgatgtga gtagtacgat atataacaat
gaggtgctcc atcaaccact ttctgaagct 3600 caaaggaaat ccaaaagcct
aaaaattaat ctcaattatg caggagatgc tctaagagaa 3660 aatacattgg
tttcagaaca tgcacaaaga gaccaacgtg aaacacagtg tcaaatgaag 3720
gaagctgaac acatgtatca aaacgaacaa gataatgtga acaaacacac tgaacagcag
3780 gagtctctag atcagaaatt atttcaacta caaagcaaaa atatgtggct
tcaacagcaa 3840 ttagttcatg cacataagaa agctgacaac aaaagcaaga
taacaattga tattcatttt 3900 cttgagagga aaatgcaaca tcatctccta
aaagagaaaa atgaggagat atttaattac 3960 aataaccatt taaaaaaccg
tatatatcaa tatgaaaaag agaaagcaga aacagaaaac 4020 tcatga 4026 6 1341
PRT Homo sapiens 6 Met Thr Lys Arg Lys Lys Thr Ile Asn Leu Asn Ile
Gln Asp Ala Gln 1 5 10 15 Lys Arg Thr Ala Leu His Trp Ala Cys Val
Asn Gly His Glu Glu Val 20 25 30 Val Thr Phe Leu Val Asp Arg Lys
Cys Gln Leu Asp Val Leu Asp Gly 35 40 45 Glu His Arg Thr Pro Leu
Met Lys Ala Leu Gln Cys His Gln Glu Ala 50 55 60 Cys Ala Asn Ile
Leu Ile Asp Ser Gly Ala Asp Ile Asn Leu Val Asp 65 70 75 80 Val Tyr
Gly Asn Met Ala Leu His Tyr Ala Val Tyr Ser Glu Ile Leu 85 90 95
Ser Val Val Ala Lys Leu Leu Ser His Gly Ala Val Ile Glu Val His 100
105 110 Asn Lys Ala Ser Leu Thr Pro Leu Leu Leu Ser Ile Thr Lys Arg
Ser 115 120 125 Glu Gln Ile Val Glu Phe Leu Leu Ile Lys Asn Ala Asn
Ala Asn Ala 130 135 140 Val Asn Lys Tyr Lys Cys Thr Ala Leu Met Leu
Ala Val Cys His Gly 145 150 155 160 Ser Ser Glu Ile Val Gly Met Leu
Leu Gln Gln Asn Val Asp Val Phe 165 170 175 Ala Ala Asp Ile Cys Gly
Val Thr Ala Glu His Tyr Ala Val Thr Cys 180 185 190 Gly Phe His His
Ile His Glu Gln Ile Met Glu Tyr Ile Arg Lys Leu 195 200 205 Ser Lys
Asn His Gln Asn Thr Asn Pro Glu Gly Thr Ser Ala Gly Thr 210 215 220
Pro Asp Glu Ala Ala Pro Leu Ala Glu Arg Thr Pro Asp Thr Ala Glu 225
230 235 240 Ser Leu Val Glu Lys Thr Pro Asp Glu Ala Ala Pro Leu Val
Glu Arg 245 250 255 Thr Pro Asp Thr Ala Glu Ser Leu Val Glu Lys Thr
Pro Asp Glu Ala 260 265 270 Ala Ser Leu Val Glu Gly Thr Ser Asp Lys
Ile Gln Cys Leu Glu Lys 275 280 285 Ala Thr Ser Gly Lys Phe Glu Gln
Ser Ala Glu Glu Thr Pro Arg Glu 290 295 300 Ile Thr Ser Pro Ala Lys
Glu Thr Ser Glu Lys Phe Thr Trp Pro Ala 305 310 315 320 Lys Gly Arg
Pro Arg Lys Ile Ala Trp Glu Lys Lys Glu Asp Thr Pro 325 330 335 Arg
Glu Ile Met Ser Pro Ala Lys Glu Thr Ser Glu Lys Phe Thr Trp 340 345
350 Ala Ala Lys Gly Arg Pro Arg Lys Ile Ala Trp Glu Lys Lys Glu Thr
355 360 365 Pro Val Lys Thr Gly Cys Val Ala Arg Val Thr Ser Asn Lys
Thr Lys 370 375 380 Val Leu Glu Lys Gly Arg Ser Lys Met Ile Ala Cys
Pro Thr Lys Glu 385 390 395 400 Ser Ser Thr Lys Ala Ser Ala Asn Asp
Gln Arg Phe Pro Ser Glu Ser 405 410 415 Lys Gln Glu Glu Asp Glu Glu
Tyr Ser Cys Asp Ser Arg Ser Leu Phe 420 425 430 Glu Ser Ser Ala Lys
Ile Gln Val Cys Ile Pro Glu Ser Ile Tyr Gln 435 440 445 Lys Val Met
Glu Ile Asn Arg Glu Val Glu Glu Pro Pro Lys Lys Pro 450 455 460 Ser
Ala Phe Lys Pro Ala Ile Glu Met Gln Asn Ser Val Pro Asn Lys 465 470
475 480 Ala Phe Glu Leu Lys Asn Glu Gln Thr Leu Arg Ala Asp Pro Met
Phe 485 490 495 Pro Pro Glu Ser Lys Gln Lys Asp Tyr Glu Glu Asn Ser
Trp Asp Ser 500 505 510 Glu Ser Leu Cys Glu Thr Val Ser Gln Lys Asp
Val Cys Leu Pro Lys 515 520 525 Ala Thr His Gln Lys Glu Ile Asp Lys
Ile Asn Gly Lys Leu Glu Glu 530 535 540 Ser Pro Asn Lys Asp Gly Leu
Leu Lys Ala Thr Cys Gly Met Lys Val 545 550 555 560 Ser Ile Pro Thr
Lys Ala Leu Glu Leu Lys Asp Met Gln Thr Phe Lys 565 570 575 Ala Glu
Pro Pro Gly Lys Pro Ser Ala Phe Glu Pro Ala Thr Glu Met 580 585 590
Gln Lys Ser Val Pro Asn Lys Ala Leu Glu Leu Lys Asn Glu Gln Thr 595
600 605 Trp Arg Ala Asp Glu Ile Leu Pro Ser Glu Ser Lys Gln Lys Asp
Tyr 610 615 620 Glu Glu Asn Ser Trp Asp Thr Glu Ser Leu Cys Glu Thr
Val Ser Gln 625 630 635 640 Lys Asp Val Cys Leu Pro Lys Ala Ala His
Gln Lys Glu Ile Asp Lys 645 650 655 Ile Asn Gly Lys Leu Glu Gly Ser
Pro Val Lys Asp Gly Leu Leu Lys 660 665 670 Ala Asn Cys Gly Met Lys
Val Ser Ile Pro Thr Lys Ala Leu Glu Leu 675 680 685 Met Asp Met Gln
Thr Phe Lys Ala Glu Pro Pro Glu Lys Pro Ser Ala 690 695 700 Phe Glu
Pro Ala Ile Glu Met Gln Lys Ser Val Pro Asn Lys Ala Leu 705 710 715
720 Glu Leu Lys Asn Glu Gln Thr Leu Arg Ala Asp Glu Ile Leu Pro Ser
725 730 735 Glu Ser Lys Gln Lys Asp Tyr Glu Glu Ser Ser Trp Asp Ser
Glu Ser 740 745 750 Leu Cys Glu Thr Val Ser Gln Lys Asp Val Cys Leu
Pro Lys Ala Thr 755 760 765 His Gln Lys Glu Ile Asp Lys Ile Asn Gly
Lys Leu Glu Glu Ser Pro 770 775 780 Asp Asn Asp Gly Phe Leu Lys Ala
Pro Cys Arg Met Lys Val Ser Ile 785 790 795 800 Pro Thr Lys Ala Leu
Glu Leu Met Asp Met Gln Thr Phe Lys Ala Glu 805 810 815 Pro Pro Glu
Lys Pro Ser Ala Phe Glu Pro Ala Ile Glu Met Gln Lys 820 825 830 Ser
Val Pro Asn Lys Ala Leu Glu Leu Lys Asn Glu Gln Thr Leu Arg 835 840
845 Ala Asp Gln Met Phe Pro Ser Glu Ser Lys Gln Lys Lys Val Glu Glu
850 855 860 Asn Ser Trp Asp Ser Glu Ser Leu Arg Glu Thr Val Ser Gln
Lys Asp 865 870 875 880 Val Cys Val Pro Lys Ala Thr His Gln Lys Glu
Met Asp Lys Ile Ser 885 890 895 Gly Lys Leu Glu Asp Ser Thr Ser Leu
Ser Lys Ile Leu Asp Thr Val 900 905 910 His Ser Cys Glu Arg Ala Arg
Glu Leu Gln Lys Asp His Cys Glu Gln 915 920 925 Arg Thr Gly Lys Met
Glu Gln Met Lys Lys Lys Phe Cys Val Leu Lys 930 935 940 Lys Lys Leu
Ser Glu Ala Lys Glu Ile Lys Ser Gln Leu Glu Asn Gln 945 950 955 960
Lys Val Lys Trp Glu Gln Glu Leu Cys Ser Val Arg Leu Thr Leu Asn 965
970 975 Gln Glu Glu Glu Lys Arg Arg Asn Ala Asp Ile Leu Asn Glu Lys
Ile 980 985 990 Arg Glu Glu Leu Gly Arg Ile Glu Glu Gln His Arg Lys
Glu Leu Glu 995 1000 1005 Val Lys Gln Gln Leu Glu Gln Ala Leu Arg
Ile Gln Asp Ile Glu 1010 1015 1020 Leu Lys Ser Val Glu Ser Asn Leu
Asn Gln Val Ser His Thr His 1025 1030 1035 Glu Asn Glu Asn Tyr Leu
Leu His Glu Asn Cys Met Leu Lys Lys 1040 1045 1050 Glu Ile Ala Met
Leu Lys Leu Glu Ile Ala Thr Leu Lys His Gln 1055 1060 1065 Tyr Gln
Glu Lys Glu Asn Lys Tyr Phe Glu Asp Ile Lys Ile Leu 1070 1075 1080
Lys Glu Lys Asn Ala Glu Leu Gln Met Thr Leu Lys Leu Lys Glu 1085
1090 1095 Glu Ser Leu Thr Lys Arg Ala Ser Gln Tyr Ser Gly Gln Leu
Lys 1100 1105 1110 Val Leu Ile Ala Glu Asn Thr Met Leu Thr Ser Lys
Leu Lys Glu 1115 1120 1125 Lys Gln Asp Lys Glu Ile Leu Glu Ala Glu
Ile Glu Ser His His 1130 1135 1140 Pro Arg Leu Ala Ser Ala Val Gln
Asp His Asp Gln Ile Val Thr 1145 1150 1155 Ser Arg Lys Ser Gln Glu
Pro Ala Phe His Ile Ala Gly Asp Ala 1160 1165 1170 Cys Leu Gln Arg
Lys Met Asn Val Asp Val Ser Ser Thr Ile Tyr 1175 1180 1185 Asn Asn
Glu Val Leu His Gln Pro Leu Ser Glu Ala Gln Arg Lys 1190 1195 1200
Ser Lys Ser Leu Lys Ile Asn Leu Asn Tyr Ala Gly Asp Ala Leu 1205
1210 1215 Arg Glu Asn Thr Leu Val Ser Glu His Ala Gln Arg Asp Gln
Arg 1220 1225 1230 Glu Thr Gln Cys Gln Met Lys Glu Ala Glu His Met
Tyr Gln Asn 1235 1240 1245 Glu Gln Asp Asn Val Asn Lys His Thr Glu
Gln Gln Glu Ser Leu 1250 1255 1260 Asp Gln Lys Leu Phe Gln Leu Gln
Ser Lys Asn Met Trp Leu Gln 1265 1270 1275 Gln Gln Leu Val His Ala
His Lys Lys Ala Asp Asn Lys Ser Lys 1280 1285 1290 Ile Thr Ile Asp
Ile His Phe Leu Glu Arg Lys Met Gln His His 1295 1300 1305 Leu Leu
Lys Glu Lys Asn Glu Glu Ile Phe Asn Tyr Asn Asn His 1310 1315 1320
Leu Lys Asn Arg Ile Tyr Gln Tyr Glu Lys Glu Lys Ala Glu Thr 1325
1330 1335 Glu Asn Ser 1340 7 23 PRT Homo sapiens 7 Met Thr Lys Arg
Lys Lys Thr Ile Asn Leu Asn Ile Gln Asp Ala Gln 1 5 10 15 Lys Arg
Thr Ala Leu His Trp 20 8 23 PRT Homo sapiens 8 Thr Ser Glu Lys Phe
Thr Trp Pro Ala Lys Gly Arg Pro Arg Lys Ile 1 5 10 15 Ala Trp Glu
Lys Lys Glu Asp 20 9 23 PRT Homo sapiens 9 Asp Glu Ile Leu Pro Ser
Glu Ser Lys Gln Lys Asp Tyr Glu Glu Asn 1 5 10 15 Ser Trp Asp Thr
Glu Ser Leu 20 10 23 PRT Homo sapiens 10 Arg Leu Thr Leu Asn Gln
Glu Glu Glu Lys Arg Arg Asn Ala Asp Ile 1 5 10 15 Leu Asn Glu Lys
Ile Arg Glu 20 11 23 PRT Homo sapiens 11 Ala Glu Asn Thr Met Leu
Thr Ser Lys Leu Lys Glu Lys Gln Asp Lys 1 5 10 15 Glu Ile Leu Glu
Ala Glu Ile 20 12 23 PRT Homo sapiens 12 Asn Tyr Asn Asn His Leu
Lys Asn Arg Ile Tyr Gln Tyr Glu Lys Glu 1 5 10 15 Lys Ala Glu Thr
Glu Asn Ser 20 13 9 PRT Homo sapiens 13 Leu Met Asp Met Gln Thr Phe
Lys Ala 1 5 14 9 PRT Homo sapiens 14 Lys Val Ile Ser Pro Thr Lys
Ala Leu 1 5 15 9 PRT Homo sapiens 15 Ser Ile Pro Thr Lys Ala Leu
Glu Leu 1 5 16 9 PRT Homo sapiens 16 Leu Glu Leu Lys Asn Glu Gln
Thr Leu 1 5 17 9 PRT Homo sapiens 17 Thr Val Ser Gln Lys Asp Val
Cys Leu 1 5 18 9 PRT Homo sapiens 18 Ser Val Pro Asn Lys Ala Leu
Glu Leu 1 5 19 9 PRT Homo sapiens 19 Cys Glu Thr Val Ser Gln Lys
Asp Val 1 5 20 9 PRT Homo sapiens 20 Lys Ile Asn Gly Lys Leu Glu
Glu Ser 1 5 21 9 PRT Homo sapiens 21 Ser Leu Val Glu Lys Thr Pro
Asp Glu 1 5 22 9 PRT Homo sapiens 22 Ser Leu Cys Glu Thr Val Ser
Gln Lys 1 5 23 9 PRT Homo sapiens 23 Glu Ile Asp Lys Ile Asn Gly
Lys Leu 1 5 24 9 PRT Homo sapiens 24 Met Leu Leu Gln Gln Asn Val
Asp Val 1 5 25 9 PRT Homo sapiens 25 Asn Met Trp Leu Gln Gln Gln
Leu Val 1 5 26 9 PRT Homo sapiens 26 Phe Leu Val Asp Arg Lys Cys
Gln Leu 1 5 27 9 PRT Homo sapiens 27 Tyr Leu Leu His Glu Asn Cys
Met Leu 1 5 28 9 PRT Homo sapiens 28 Ser Leu Phe Glu Ser Ser Ala
Lys Ile 1 5 29 9 PRT Homo sapiens 29 Lys Ile Thr Ile Asp Ile His
Phe Leu 1
5 30 9 PRT Homo sapiens 30 Gln Leu Gln Ser Lys Asn Met Trp Leu 1 5
31 9 PRT Homo sapiens 31 Ser Leu Asp Gln Lys Leu Phe Gln Leu 1 5 32
9 PRT Homo sapiens 32 Phe Leu Leu Ile Lys Asn Ala Asn Ala 1 5 33 9
PRT Homo sapiens 33 Lys Ile Leu Asp Thr Val His Ser Cys 1 5 34 9
PRT Homo sapiens 34 Ser Leu Ser Lys Ile Leu Asp Thr Val 1 5 35 9
PRT Homo sapiens 35 Ile Leu Ile Asp Ser Gly Ala Asp Ile 1 5 36 9
PRT Homo sapiens 36 Lys Val Met Glu Ile Asn Arg Glu Val 1 5 37 9
PRT Homo sapiens 37 Lys Leu Leu Ser His Gly Ala Val Ile 1 5 38 9
PRT Homo sapiens 38 Ala Val Tyr Ser Glu Ile Leu Ser Val 1 5 39 9
PRT Homo sapiens 39 Lys Met Asn Val Asp Val Ser Ser Thr 1 5 40 9
PRT Homo sapiens 40 Ile Leu Ser Val Val Ala Lys Leu Leu 1 5 41 9
PRT Homo sapiens 41 Val Leu Ile Ala Glu Asn Thr Met Leu 1 5 42 9
PRT Homo sapiens 42 Lys Leu Ser Lys Asn His Gln Asn Thr 1 5 43 9
PRT Homo sapiens 43 Ser Leu Thr Pro Leu Leu Leu Ser Ile 1 5 44 9
PRT Homo sapiens 44 Ser Gln Tyr Ser Gly Gln Leu Lys Val 1 5 45 9
PRT Homo sapiens 45 Lys Glu Leu Glu Val Lys Gln Gln Leu 1 5 46 9
PRT Homo sapiens 46 Gln Ile Met Glu Tyr Ile Arg Lys Leu 1 5 47 9
PRT Homo sapiens 47 Ala Met Leu Lys Leu Glu Ile Ala Thr 1 5 48 9
PRT Homo sapiens 48 Val Leu His Gln Pro Leu Ser Glu Ala 1 5 49 9
PRT Homo sapiens 49 Gly Leu Leu Lys Ala Thr Cys Gly Met 1 5 50 9
PRT Homo sapiens 50 Gly Leu Leu Lys Ala Asn Cys Gly Met 1 5 51 9
PRT Homo sapiens 51 Gln Gln Leu Glu Gln Ala Leu Arg Ile 1 5 52 9
PRT Homo sapiens 52 Cys Met Leu Lys Lys Glu Ile Ala Met 1 5 53 9
PRT Homo sapiens 53 Glu Gln Met Lys Lys Lys Phe Cys Val 1 5 54 9
PRT Homo sapiens 54 Ile Gln Lys Ile Glu Leu Lys Ser Val 1 5 55 9
PRT Homo sapiens 55 Ser Val Pro Asn Lys Ala Phe Glu Leu 1 5 56 9
PRT Homo sapiens 56 Ser Ile Tyr Gln Lys Val Met Glu Ile 1 5 57 9
PRT Homo sapiens 57 Asn Leu Asn Tyr Gln Gly Asp Ala Leu 1 5 58 9
PRT Homo sapiens 58 Ala Val Gln Asp His Asp Gln Ile Val 1 5 59 9
PRT Homo sapiens 59 Leu Ile Ala Glu Asn Thr Met Leu Thr 1 5 60 9
PRT Homo sapiens 60 Phe Glu Leu Lys Asn Glu Gln Thr Leu 1 5 61 9
PRT Homo sapiens 61 Phe Glu Ser Ser Ala Lys Ile Gln Val 1 5 62 9
PRT Homo sapiens 62 Gly Val Thr Ala Glu His Tyr Ala Val 1 5 63 9
PRT Homo sapiens 63 Arg Val Thr Ser Asn Lys Thr Lys Val 1 5 64 9
PRT Homo sapiens 64 Thr Val Ser Gln Lys Asp Val Cys Val 1 5 65 9
PRT Homo sapiens 65 Lys Ser Gln Glu Pro Ala Phe His Ile 1 5 66 9
PRT Homo sapiens 66 Lys Asn Leu Ile Ala Glu Asn Thr Met 1 5 67 9
PRT Homo sapiens 67 Met Leu Lys Leu Glu Ile Ala Thr Leu 1 5 68 9
PRT Homo sapiens 68 Glu Ile Leu Ser Val Val Ala Lys Leu 1 5 69 9
PRT Homo sapiens 69 Met Leu Lys Lys Glu Ile Ala Met Leu 1 5 70 9
PRT Homo sapiens 70 Leu Leu Lys Glu Lys Asn Glu Glu Ile 1 5 71 9
PRT Homo sapiens 71 Ala Leu Arg Ile Gln Asp Ile Glu Leu 1 5 72 9
PRT Homo sapiens 72 Lys Ile Arg Glu Glu Leu Gly Arg Ile 1 5 73 9
PRT Homo sapiens 73 Thr Leu Lys Leu Lys Glu Glu Ser Leu 1 5 74 9
PRT Homo sapiens 74 Ile Leu Asn Glu Lys Ile Arg Glu Glu 1 5 75 9
PRT Homo sapiens 75 Val Leu Lys Lys Lys Leu Ser Glu Ala 1 5 76 9
PRT Homo sapiens 76 Gly Thr Ser Asp Lys Ile Gln Cys Leu 1 5 77 9
PRT Homo sapiens 77 Gly Ala Asp Ile Asn Leu Val Asp Val 1 5 78 9
PRT Homo sapiens 78 Glu Leu Cys Ser Val Arg Leu Thr Leu 1 5 79 9
PRT Homo sapiens 79 Ser Val Glu Ser Asn Leu Asn Gln Val 1 5 80 9
PRT Homo sapiens 80 Ser Leu Lys Ile Asn Leu Asn Tyr Ala 1 5 81 9
PRT Homo sapiens 81 Lys Thr Pro Asp Glu Ala Ala Ser Leu 1 5 82 9
PRT Homo sapiens 82 Ala Thr Cys Gly Met Lys Val Ser Ile 1 5 83 9
PRT Homo sapiens 83 Leu Ser His Gly Ala Val Ile Glu Val 1 5 84 9
PRT Homo sapiens 84 Glu Ile Ala Met Leu Lys Leu Glu Ile 1 5 85 9
PRT Homo sapiens 85 Ala Glu Leu Gln Met Thr Leu Lys Leu 1 5 86 9
PRT Homo sapiens 86 Val Phe Ala Ala Asp Ile Cys Gly Val 1 5 87 9
PRT Homo sapiens 87 Pro Ala Ile Glu Met Gln Asn Ser Val 1 5 88 9
PRT Homo sapiens 88 Glu Ile Phe Asn Tyr Asn Asn His Leu 1 5 89 9
PRT Homo sapiens 89 Ile Leu Lys Glu Lys Asn Ala Glu Leu 1 5 90 9
PRT Homo sapiens 90 Gln Leu Val His Ala His Lys Lys Ala 1 5 91 9
PRT Homo sapiens 91 Asn Ile Gln Asp Ala Gln Lys Arg Thr 1 5 92 9
PRT Homo sapiens 92 Asn Leu Val Asp Val Tyr Gly Asn Met 1 5 93 9
PRT Homo sapiens 93 Lys Cys Thr Ala Leu Met Leu Ala Val 1 5 94 9
PRT Homo sapiens 94 Lys Ile Gln Cys Leu Glu Lys Ala Thr 1 5 95 9
PRT Homo sapiens 95 Lys Ile Ala Trp Glu Lys Lys Glu Thr 1 5 96 9
PRT Homo sapiens 96 Ile Ala Trp Glu Lys Lys Glu Asp Thr 1 5 97 9
PRT Homo sapiens 97 Val Gly Met Leu Leu Gln Gln Asn Val 1 5 98 9
PRT Homo sapiens 98 Val Lys Thr Gly Cys Val Ala Arg Val 1 5 99 9
PRT Homo sapiens 99 Ala Leu His Tyr Ala Val Tyr Ser Glu 1 5 100 9
PRT Homo sapiens 100 Gln Met Lys Lys Lys Phe Cys Val Leu 1 5 101 9
PRT Homo sapiens 101 Ala Leu Gln Cys His Gln Glu Ala Cys 1 5 102 9
PRT Homo sapiens 102 Ser Glu Gln Ile Val Glu Phe Leu Leu 1 5 103 9
PRT Homo sapiens 103 Ala Val Ile Glu Val His Asn Lys Ala 1 5 104 9
PRT Homo sapiens 104 Ala Val Thr Cys Gly Phe His His Ile 1 5 105 9
PRT Homo sapiens 105 Ala Cys Leu Gln Arg Lys Met Asn Val 1 5 106 9
PRT Homo sapiens 106 Ser Leu Val Glu Gly Thr Ser Asp Lys 1 5
* * * * *